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Atherosclerosis and its most significant clinical repercussion, 
cardiovascular disease (CVD), is the leading cause of morbidity and 
mortality in postmenopausal women, with a substantial global public 
health impact as a consequence. Vascular endothelial dysfunction, which 
is potentiated by decreasing estrogen levels in the menopausal transition 
period, is an early hallmark of developing CVD. The action of estrogens 
has been widely investigated in many critical areas of atherogenesis, due 
to the presence of estrogen receptors in the vascular system. Estrogens 
can have both positive and negative effects on the vascular wall 
depending on the stage of atherosclerosis disease. The estrogen response 
is mediated by different mechanisms, involving either genomic pathways 
requiring ligand-activated transcription with posterior modulation of 
protein synthesis, or non-genomic pathways, mainly affecting enzyme 
activity and rapid signaling cascades. 
The vigorous debate surrounding the risk/benefit profile of 
estrogen in the development and timing of CVD in postmenopausal 
women is still ongoing. Evidence that the progestin component of 
hormone therapy increases breast cancer risk or even attenuates the 
potential beneficial effects of estrogens has been paralleled by a decline 
in the use of hormone therapy in postmenopausal women in recent years. 
This data, along with problems associated with long-term use of 




molecules capable of activating estrogen receptors, leading to 
transcriptional activity in some tissues but not in others. Selective 
estrogen receptor modulators (SERMs) and more recently, tissue 
selective estrogen complex (TSEC) have been developed as alternatives 
to hormonal replacement therapy (HRT). 
Previous experimental studies have shown the capacity of 
estrogens and second-generation SERM raloxifene to promote 
endothelial cell regrowth and improve cell survival rate in the early 
stages of atherosclerosis disease. Clinical trials involving bazedoxifene 
or conjugated estrogens plus bazedoxifene have shown cardiovascular 
safety in healthy postmenopausal women. However, one research group 
working with an atherosclerotic animal model in monkeys demonstrated 
that therapeutic application of bazedoxifene had no effect on 
atherosclerosis. What is more, bazedoxifene completely impeded the 
antiatherosclerotic effects of estrogen treatment in the mentioned study. 
To date no report has been published of bazedoxifene’s effect on 
vascular cell proliferation and the mechanisms involved using an in vitro 
model. 
This study was designed to evaluate the effect of bazedoxifene on 
the proliferation of human umbilical arterial endothelial cells (HUAEC) 
compared with estradiol, raloxifene and the combination of bazedoxifene 
plus estradiol. Additionally, we assessed whether the process was 
associated with changes in the protein and gene expression of key cell 
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cycle regulators such as cyclin A, cyclin B, cyclin D1 and p27Kip1 in both 
fresh and cryopreserved endothelial cells.  
HUAEC were obtained from umbilical cords from healthy 
women at time of delivery in a Hospital Clinico of Valencia maternity 
ward. Umbilical cords were processed under specific conditions in the 
laboratory of the  Pediatrics, Obstetrics, and Gynecology Department in 
the Faculty of Medicine. Primary culture and subcultures were carried 
out until sufficient endothelial cells were obtained for the study. Cells 
were synchronized at the G0 and G1 cell cycle phases, and active 
treatments were applied. Cell proliferation was measured using the 
Colorimetric Cell-Proliferation Kit II (XTT). Western blot experiments 
measured changes in protein expression and quantitative real-time 
polymerase chain reaction tested for gene expression alterations.  
At increasing doses bazedoxifene alone showed moderately 
enhanced increased cell proliferation, a similar increase to estradiol and 
raloxifene. No significant results on proliferation were found after 
concurrent cell treatment with bazedoxifene plus estradiol. 
Immunoblotting assays detected an isolated increase in cyclin A and 
p27Kip1 expression after treatment with estradiol, even though no 
significant changes in gene expression were associated with 
bazedoxifene, estradiol, raloxifene, or bazedoxifene plus estradiol for 
any cyclins. Analysis of the previous cryopreserved status of endothelial 




cyclins compared to the fresh endothelial cells. In contrast, no significant 
trend was observed in their RNA profile. 
In a broader perspective, the results of this study show for the 
first time the capacity of bazedoxifene to promote endothelial cell 
proliferation in an in vitro model. This beneficial effect has been 
corroborated in the literature for its predecessors estradiol and raloxifene, 
as is also confirmed in our work. The bazedoxifene-induced 
improvement in cell proliferation may facilitate endothelial regeneration 
and repair and thus contribute to the recovery of vascular functions 
during the early stages of atherosclerosis development. This observation 
turns the spotlight on bazedoxifene as a potential therapeutic target in 
CVD prevention when administered to women during the initial 
postmenopausal period.   
Although our results were inconclusive for the gene and protein 
expression of cell cycle key regulators such as cyclin A, cyclin B, cyclin 
D1 and p27Kip1 associated with bazedoxifene treatment, further 
experimental studies are nonetheless warranted. These should include the 
full panel of key regulators in cell cycle machinery to confirm whether 
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1. 1. Risk of cardiovascular disease in postmenopausal women 
 Changes in population dynamics are steadily increasing life 
expectancy, and it is estimated that roughly a third of woman's life will 
be spent beyond the menopausal transition. CVD seems to reflect the 
long-term consequences of aging and estrogen deficiency, causing a 
relative impact on women’s welfare, morbidity, and mortality, in 
addition to a significant economic impact on healthcare service. 
 
1.1.1. Prevalence and incidence of CVD 
 CVD remains the leading cause of death globally, even though 
the incidence of cardiovascular disease and death has declined markedly 
in a high-income countries (HICs) over the last two decades, being 
cancer responsible for twice as many deaths as CDV, according to a new 
report from the Prospective Urban Rural Epidemiology (PURE) study 
(1). Coronary heart disease (CHD), stroke, and venous thromboembolic 
disease (VTD) are the principal clinical endpoints of CVD. 
Approximately 45% of deaths are attributed to CVD in Europe, and 31% 
in the United States. This rate has decreased by up to 15% over the last 
ten years, but it is still the most common cause of mortality overall (2), 
(3). According to the latest European Cardiovascular Disease Statistics 
data, the group of circulatory system diseases remained the leading cause 
of death for women in Spain, followed by tumors and respiratory 
disorders. Including all its forms, CVD is responsible for approximately 
115,000 deaths in Spain each year (3).       
Introduction 
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A similarly strong gender pattern was found regarding both 
prevalence and clinical presentation of CVD. The prevalence of CVD in 
women of reproductive age is lower than in men, rising substantially 
when women lose their reproductive capacity and ovarian hormonal 
production on reaching menopause (Figure 1) (2). If we evaluate the 
prevalence of CVD by age group, men under 60 years old show a higher 
frequency of CV events, while after that numbers tend to equalize, and 
women are typically around four years older than men at onset (≈75 
years compared with 71 years). 
  
Figure 1. Prevalence of cardiovascular disease in adults by age and gender 
group. These include data on coronary heart disease, heart failure, stroke, and 
hypertension taken from American National Health and Nutrition Examination 
Survey: 2009–2012. Data taken from American National Health and Nutrition 
Examination Survey: 2013–2016 (2). 
 
Most often the problem lies not only with a lower perception of 
CV risk in initially asymptomatic post-menopausal women, but also with 
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delayed diagnosis and an oncoming acute CV event. The differences in 
risk between men and women could be related to the possible influence 
of sex hormones, as many observational studies have demonstrated a 
protective effect for estrogens against CVD in premenopausal women.  
To tackle this disease approaches are based around modification 
of the especially modifiable risk factors, and early diagnosis through 
advances in imaging techniques. Similarly, investigation into the 
pathophysiology of CVD and a better understanding of how sexual 
hormones act in this dysfunction opens up a promising field in terms of 
early diagnosis and appropriate treatment. 
1.1.2 Clinical aspects of menopause 
Hormone levels changes occurring during the menopausal 
transition, particularly the decline in quality of estrogens, can manifest 
clinical symptoms, which are generally divided into short-term and long-
term consequences. Short-term symptoms are irregular bleeding, 
vasomotor signs (hot flashes and night sweats), local symptoms (skin 
changes, vulvovaginal atrophy), and even psychological symptoms 
(depressed mood, anxiety, irritability, lack of energy, etc.).  
Around 75% of postmenopausal women will suffer hot flashes 
and night sweats, which constitute the most common and most frequent 
symptoms of menopause, related both to endothelial dysfunction and 
estrogen deprivation. Their frequency and duration are variable (from a 
few seconds to an hour), more frequent during the night, and are often 
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accompanied by palpitations and a sense of anxiety. They may appear a 
few years before menopause and last up to about five years, although 
their intensity decreases with time. 
The genitourinary syndrome of menopause (GSM), consisting of 
the combination of symptoms such as thinning of the epithelium, 
urogenital atrophy, decreased vaginal and cervical secretions, 
dyspareunia, itching, dryness, and burning, occurs at the urogenital level 
as a result of estrogen deficiency. GSM is common, affecting around 
50% of postmenopausal women. Its clinical manifestations can impact 
negatively on the quality of women´s lives, including sexual 
relationships and emotional well-being.  
Long-term effects are characterized by two fundamental 
problems, osteoporosis and CVD; the latter is the focus of our work. 
Given that sex hormones contribute to bone homeostasis, their decrease 
may lead to a loss of bone mass, at both cortical and trabecular bone 
level. A high rate of bone remodeling occurs across menopause, leading 
to an increase in the resorption mediated by the osteoclasts, which are 
greater in number; the osteoblasts, although also in greater quantity, are 
not able to compensate. This situation will lead to a higher risk of bone 
fractures, basically vertebral and hip fractures, which have high 
morbidity and mortality in elderly patients. 
Due to the decrease during menopause in the circulating level of 
estrogens, with a comparatively increased androgen concentration, body 
fat distribution changes, with an increase in visceral adiposity. There are 
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also alterations in lipid regulation with a marked pro-atherogenic profile, 
hypertension and insulin resistance development (4). All these changes 
represent independent risk factors for developing diseases such as 
diabetes mellitus type II, metabolic syndrome or CVD. 
These changes are concurrent with an increase in 
proinflammatory cytokines. Chronic inflammation is a significant factor 
in atherosclerosis and atherothrombosis. 
 
1.1.3 Predicting CV risk factors  
Regardless of the origin of the atherogenesis-inducing factors, the 
first structure affected is the endothelial cell layer, due to its privileged 
position, with sensor and effector architecture. Impairment in endothelial 
function can be due to multiple causes such as high blood pressure, 
diabetes mellitus, genetic alterations, free radicals produced by tobacco 
or even microorganisms such as Chlamydia pneumoniae or Herpes virus 
(5). An extensive case-control study (INTERHEART) evaluating the 
effect of modifiable risk factors associated with acute heart events in 
both sexes in 52 countries worldwide, found that smoking was the 
leading preventable risk factor, followed by hypertension, abnormal lipid 
concentration, abdominal obesity, diabetes, excessive alcohol intake and 
lack of regular physical activity, all together responsible for 90% of the 
risk of an initial acute myocardial infarction (6). However, the traditional 
Framingham risk score and other similar assessment models that take 
into account major CV risk factors (cigarette smoking, hypertension, 
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hypercholesterolemia, diabetes mellitus, and age) fail to predict nearly 
50% of CV events in asymptomatic patients (7). Defining the origin and 
the magnitude of particular points in the development of CVD is a 
primary focus in preventing future clinical events. 
 There is increasing scientific evidence supporting the hypothesis 
that vascular endothelial dysfunction is a pivotal promoter in the 
atherosclerosis and thrombosis processes, and independently predicts 
acute cardiovascular events in patients with and without established 
CVD (8), (9). Asymptomatic women are more likely to have a higher 
occurrence of microvascular lesions than men, especially during the 
transitional period when sex hormone levels change dramatically (10). 
Indeed, the main concern is that a significant proportion of post-
menopausal women with a silent form of atherosclerosis are classified 
within low/medium CVD risk groups, allowing it to progress to 
irreversible chronic disease. It is therefore crucial to develop strategies 
addressed at improving diagnosis, prognosis, and treatment in these 
women (11).  
To date no specific biomarkers of endothelial damage have been 
identified, owing to their tissue and vascular region variability, which 
precludes reliable systematic screening. The invasive approach to 
endothelial function using quantitative angiography and intravascular 
ultrasound has the highest clinical value, but is severely limited by the 
aggressiveness of the methods (12). During recent decades other non-
invasive techniques have been investigated, such as measuring flow-
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mediated dilation (FMD) in the brachial artery, to evaluate the health of 
the pan arterial wall and add prognostic information on CV risk (7).  
Another independent factor effecting CV risk is menopause, as 
was revealed in the Framingham Heart Study, where a post-menopausal 
woman had a two-fold higher incidence of CV events in comparison with 
a pre-menopausal woman of the same age (13). Estrogen deficiency is 
involved negatively not only in the cardiovascular system but also in a 
decrease in serum androgen levels, which is associated with deleterious 
effects on endothelial function and advanced stage of atherosclerosis 
(14). Taking this into account, it is noteworthy that the availability of sex 
steroids in women´s blood could affect the particular of CVD profile, 
meaning that women with either artificial or early menopause have a 
notably higher risk of CVD (15).  
Data from the large prospective and observational study SWAN 
(Study of Women's Health Across the Nation) including women of 
different ethnic groups during the first 12 months of post-menopausal 
amenorrhea showed that the main change in CVD risk factors occurs at 
the level of cholesterol metabolism, including total cholesterol, low-
density lipoprotein cholesterol (LDL) and apolipoprotein B, which 
increase exponentially through this period. Note that these particles 
change their conformation, becoming denser, smaller and atherogenic 
(16). A smaller population of the SWAN was studied to determine how 
different patterns of circulating estradiol (E2) and follicle-stimulating 
hormone (FSH) during the years around the final menstrual period 
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(FMP) influence the risk markers of atherosclerosis after menopause. 
The group of women with low levels of E2 after menopause and lower 
FSH rise after their FMP may be more protected from flourishing 
atherosclerosis. However, women with high levels of E2 after 
menopause and medium or high FSH rises were associated with greater 
atherosclerotic risk (17). It is still unclear if these hormone pathway 
findings reflect an endogenous response to atherosclerosis development 
over time or a result from direct harmful actions of elevated levels of E2, 
but they could change future views of the transitional period of 
menopause based today mainly on clinical concepts. 
 
1.2. Estrogens and cardiovascular disease 
1.2.1 Biological mechanisms of estrogen action  
Estrogens play an essential role in the regulation of normal 
physiology, aging, and many disease states. Therefore, advancing 
knowledge of estrogen signaling pathways is of great importance, both to 
interpret their role at the level of different organs and tissues and to 
understand the symptoms that cause their deficit, as occurs at 
menopause. 
Estrogens are steroid sex hormones produced in the adrenal 
glands and ovaries, predominantly in women before menopause. Four 
active forms can be highlighted: estrone (E1), estriol (E3), estetrol (E4) 
(18), which is secreted only during pregnancy, and estradiol (E2) which 
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is the most prevalent in the organism. It is well known that the cellular 
response to estrogen is mediated by the existence of at least three types 
of cellular receptors, also expressed in the cells of the CV system. The 
´classical´ nuclear estrogen receptors α (ERα) and β (ERβ) reflect the 
genomic pathway because of their ligand-activated transcription factor 
action; the membrane-associated plasma receptors, located at the 
caveolae level, are principally responsible for rapid estrogen effects due 
to a non-genomic pathway (19).   
Both classical isoforms of ER share a conventional structure, 
which contains five different domains and six regions (Figure 2). They  
perform their functions independently while simultaneously interacting 
with each other:  
 The A/B Domain, located in the amino terminus, is 
responsible for driving the activation function site 1, AF1, 
and is the site of interaction of other transcription factors.  
 The C Domain, DNA-binding domain, acting on specific 
sequences in the target genes, known as estrogen-response 
elements (ERE). The result of the binding between ER to 
ERE affects gene expression by modulating 
transcriptional events.  
 The D Domain is a region that gives flexibility to the ER 
for conformational changes and allows its movement 
towards the nucleus after its synthesis.  
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Although most tissues express both ER subtypes, their 
distribution seems to be tissue-specific. ERα is predominant in the 
female reproductive system and the mammary glands, although it is also 
expressed in testicles, liver, and kidney. ERβ is present in granulosa cells 
of the ovary, bone, central nervous system, and prostatic tissue (21). The 
presence of both types of receptors has been identified by different 
techniques in the cardiovascular system, including endothelial cells, 
smooth muscle cells, and fibroblasts, although their contribution in the 
regulation of vascular effects remains the target of several lines of 
research (22). On the one hand, an impaired vascular function has been 
described as a consequence of the absence of ERα in a mice model; 
therefore its presence is probably critical for the protective estrogenic 
effect in the atherosclerotic process (23). On the other hand, ERβ’s 
broader distribution in the organism is well known, as it its increased 
overexpression in areas of vascular damage, coronary calcification and 
atherosclerosis in both women and men (24), (25). In conclusion, both 
ERα and ERβ may have different roles in the vascular wall, and both 
their physiological and their pathological involvement in the 
cardiovascular system is an issue under investigation (26).   
The ´classical´ model of estrogen receptor signaling establishes 
that ERα and ERβ act as ligand-activated transcription factors. Each 
ligand can induce a different conformation of the receptor, resulting in 
multiple cell effects. After binding, estrogen receptors interact with ERE 
in the promoter region of target genes. The corresponding genes are then 
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activated, transcribed to mRNA and lead finally to the synthesis of 
specific proteins. This process usually requires at least 1-2 hours after 
starting hormone treatment (19).  
Moreover, the ligand-receptor complex may interact with a set of 
proteins called RIPs (Receptor Interacting Proteins), coactivators and 
coreceptors, which act as intermediate markers between the ER and the 
transcriptional machinery. RIPs have a broad function. On the one hand, 
they are capable of directing the AF1 areas of the target, enabling 
different degrees of access to the transcriptional machinery. On the other 
hand, RIPs can establish a link with other co-regulatory proteins in such 
a way that their differing concentration affects the final cellular response.  
 In contrast to the tardy actions of estrogens mediated by the 
genomic pathway, estrogens can also produce effects in a few seconds or 
minutes without requiring the intranuclear transcription process directly. 
This is  because estrogens may also bind to plasma membrane-associated 
subpopulations of classic ERs or a distinct membrane-associated 
receptor, thereby activating a variety of rapid intracellular signaling 
cascades (27). Therefore, it should be noted that the final cellular 
response is given by the complex interaction of transcriptional or 
"genomic" and non-transcriptional effects. Some authors report that 
activating signaling cascades could affect the transcription process, either 
through co-activating elements, by phosphorylation of the receptor or 
other transcription factors, influencing the final gene expression (28), 
(29). "Non-genomic" is therefore an inappropriate term for a pathway 
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where changes occur in transcription, so a new term, "membrane-
initiated steroid signaling” is proposed, based on the principle that these 
actions are generated from second messengers and organized kinases, 
mainly in the cell membrane. 
 This phenomenon was discovered and described for the first time 
in 1942 by Dr. Hans Seyle after observing effects immediately after the 
administration of certain steroids, in contrast to the impact of delayed 
duration (hours or days) known at that time. Later on, in 1967 it was 
observed that estrogen also caused the rapid release of cyclic AMP 
(cAMP) and immediate changes in calcium concentration in endometrial 
cells of the rat uterus (30), and specific binding sites for this hormone on 
the surface of these cells were identified (31). They showed that 
membrane ERs on the surface of these cells activate signal cascades, 
which facilitates the permeability of compounds mediated by hormones 
and the ability to transport E2 into endocytic vesicles to the nucleus 
where they exert their function.  
 One of the best reported rapid actions of estrogen occurs in 
endothelial cells where E2 can stimulate the production of cyclic 
guanosine monophosphate (cGMP) and nitric oxide synthase (eNOS), in 
addition to activating kinases involved in cell cycle regulation (19), (32), 
(33), (34), (35). The arteries of the cardiovascular system respond to 
rapid non-genotropic actions of the kinase family, causing the reduction 
of ischemic damage mediated by NO-dependent vasodilation (36), (37). 
E2 also inhibits Ca2+ channels in the vascular smooth muscle, which 
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results in improved heart perfusion (38). There are many more examples 
of this type of actions, that have been gaining increasing importance, 
constituting the focus of around 1000 publications to date. 
In certain cell types, ERs are located in the plasma membrane at 
the level of invaginations called caveolae, associated with large protein 
complexes promoting efficient signaling. The steroid actions initiated in 
the membrane appear to trigger many intracellular signaling pathways, 
including mitogen-activated protein kinase and phosphatidylinositol 3-
kinase/Akt (PI3K/Akt) activation of ion channel fluxes, generation of G 
protein-coupled receptor-mediated second messengers and stimulation of 
growth factor receptors (33).  
More recent studies have revealed that membrane-bound estrogen 
receptor or GRER (formerly known as GPR30) is an essential mediator 
of the rapid cellular effects of estrogen throughout the body. This protein 
G was later shown to be located in the rough endoplasmic reticulum, 
therefore was termed as GRER, and to bind specifically to estrogen. As a 
result of the discovery of selective synthetic ligands for GRER, both 
agonists and antagonists, as well as the use of GRER knockout mice, 
several facets of this pathway signaling are being investigated and 
significant insights have been made into GRER functions at the cellular, 
tissue and organism level (39), (40). Adenylate cyclase and c-Src are the 
two effector pathways activated after the estrogen agonist binds with the 
GRER. Both routes are involved in activating mitogen-activated protein 
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kinases (MAPK) and PI3K that can lead to the transactivation of genes, 
even ones without EREs.  
As mentioned before, a membrane receptor mediates these 
actions, but its origin is still unresolved. It could be migration of the 
nuclear receptors themselves or others linked to the hormones. Studies 
carried out support the hypothesis that the activation of signaling 
cascades against the same hormone depends on the receptors of different 
cellular compartments and the specific cell environment (41).  





Figure 3. Diagram of the different signaling pathways through the estrogen 
receptor. 
1) The classic intracellular receptor pathway. When the E2 enters the cell 
and binds to its ER, the complex formed translocates and migrates to 
the nucleus. The heterodimer interacts with ERE, transcribing to 
mRNA and leading finally to the synthesis of specific proteins that 
influence cell behavior. 
2) Estrogens can activate a subpopulation of ERs in the cell membrane 
(ERm) which trigger signaling proteins such as c-Src, a critical point in 
the activation of fast pathways through PI3K/Akt and MAPK. 
3) E2 can also be incorporated into the GRER receptor bound to the G 
protein that is located in the endoplasmic reticulum. GRER activates 
effector molecules such as cAMP and c-Src. The last mentioned 
molecule can stimulate MMPs and favor the release of Epidermal 
Growth Factor (EGF) through EGFR. Some of the signaling cascades 
are activated at the same time, such as the activation of PI3K/Akt and 
MAPK and, consequently, the release of NO in the endothelial cell. 
ER: estrogen receptor; ERE: elements of estrogen response; Pl3K/Akt: 
phosphatidylinositol 3-kinase/Akt pathway; MAPK: mitogen-activated protein kinases 
pathway; GRER: distinct membrane receptor; cAMP: cyclic adenosine monophosphate; 
c-Src: tyrosine-protein kinase; MMPs: matrix metalloproteinases; EGF: epidermal 
growth factor; EGFR: epidermal growth factor receptor; NO: nitric oxide.  
Modified from Meyer, MR (42).  
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1.2.2. Impact of estrogen effects on development of 
atherosclerosis lesion.  
 
In the pathogenesis of atherosclerosis different mechanisms 
involved have shown estrogenic sensitivity. Under physiological 
conditions, the endothelium regulates vascular tone by liberating 
vasodilator substances such as nitric oxide (NO) and prostacyclin (PGI2), 
avoiding adhesion and migration of cells from the blood into arterial 
wall, expression of their receptors, and proliferation of smooth muscle, 
thus keeping the composition of surrounding extracellular matrix intact 
(12). The progression of atheromatous plaques may be favored both by 
changes in lipid metabolism and by alterations in the capacity of the 
endothelium to release biological mediators. 
The direct effect of estrogen loss combined with other major CV 
risk factors, together contribute to endothelial cell injury by inducing 
impaired NO bioavailability and significant permeability. This mainly 
leads lipoprotein deposits to oxidize into sub endothelial space or so-
called fatty streaks. When vascular wall damage becomes persistent, it 
can lead to stable or unstable plaque formation, and become a major 
trigger for many stages of CVD. Growing evidence has reported that the 
effect of estrogens on the vascular vessels depends on how advanced the 
atherosclerosis is. The effect of estrogens on early atherogenesis could be 
neutral or even beneficial due to their capacity to promote NO release, 
improve plasma lipids levels and maintain the integrity of intimal cells 
(43).  
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1.2.3. Menopausal hormone therapy. Historical background. 
The protective effect of hormones has long been emphasized, and 
the role of estrogen therapy (ET) on the cardiovascular system has been 
broadly studied. The use of estrogens to improve climacteric 
symptomatology began in the early 1940s in the United States as a result 
of obtaining conjugated estrogens from pregnant mares’ urine, and in 
response to the book "Feminine forever" published by Robert A. Wilson 
in 1968. A similar thing had happened in Europe with the synthesis of 
the main circulating physiological hormone secreted by the female 
gonad, 17 β-estradiol. The beneficial effects of estrogen therapy have 
been proven not only in improving women's quality of life, vulvovaginal 
atrophy and climacteric symptoms, but also in reports that estrogen 
provides more significant benefits, among which are protection of the 
cardiovascular system, memory and cognitive processes, bone safety, 
skin, and even dental health. 
Numerous observational studies in the late twentieth century have 
reported that postmenopausal women who received long-term treatment 
with ET and HRT with estrogens and progestogens showed a lower risk 
for osteoporotic fractures, cardiovascular diseases and even Alzheimer’s 
disease (44). The most extensive observational study, the Nurses’ Health 
Study (NHS), strongly supported a protective cardiovascular benefit of 
HRT after menopause. More specifically, the women in the study had 
more than 40% risk reduction of CV events and a 30% decrease in 
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mortality due to CV causes (45). However, the benefits suggested in the 
observational studies were not supported by randomized, double-blind, 
placebo-controlled clinical trials in either primary prevention, Women’s 
Health Initiative (WHI) or secondary prevention, Heart 
Estrogen/Progestin Replacement Study (HERS), which instead raised 
severe doubts about its safety (46), (47).   
The WHI combined a set of randomized controlled trials and an 
observational study initiated in 1991, all of which were postulated to 
address strategies for preventing CVD, breast cancer, colorectal cancer 
and osteoporotic fractures in postmenopausal women. The hormone 
therapy trial had two arms and included asymptomatic women aged 50-
79 with an average age of 63 years. 
A first arm recruited 16,608 women with an intact uterus, who 
were randomized to receive conjugated equine estrogens (CEE) plus 
synthetic medroxyprogesterone acetate (MPA) or placebo. After a 
follow-up of just over five years, the study had to be terminated earlier 
than planned due to early reports indicating a higher incidence of breast 
cancer and an increased risk of cardiovascular events (coronary heart 
disease, pulmonary embolism, and stroke) in this combined estrogen and 
progesterone arm, specifically in women who had experienced more than 
20 years of menopause at baseline (46). 
 The second arm of the study included 10,739 women with 
hysterectomy who were randomized to CEE alone or placebo with an 




The negative message about HRT transmitted by early reports 
from the WHI study precipitated confusion among practitioners about the 
adverse effects and risks associated with the therapy. Notwithstanding,  
certain limitations in the trial design cast doubt on the discrepancy 
between animal/observational studies and randomized controlled trials. 
These include the older age of women in the clinical trial (average age 63 
years), the late timing of initiation (especially in postmenopausal women 
with an average of ten years after menopause onset), and the high mean 
body mass in these women compared with the observational studies. The 
increased risk of CV events in these women could be due to the age of 
the women included in the study, whose blood vessels had already been 
exposed to an aging process, probably with underlying asymptomatic 
atheromatous plaques. 
In the HERS study, with a similar design to WHI, the 2,763 
selected patients had a known CHD. After a mean of 4.1 years, there was 
no significant difference in the number of cardiovascular events in the 
HRT arm versus placebo, so it also ended earlier than expected (47).  
Taking this data into account, there are three mechanisms by 
which estrogens or estrogen-based therapies could be harmful to the 
cardiovascular system: they can change lipid composition by increasing 
triglyceride levels, can result in a prothrombotic effect on the coagulation 
cascade and lastly, estrogens administered orally, but not those 
administered transdermally, show proinflammatory effects including 
increased synthesis of C-reactive protein (CRP) (50). The higher risk 
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associated with oral compared with transdermal estradiol shows that the 
different of drug administration routes follow diverse metabolic 
pathways (transdermal, oral, or intravenous with or without 
progesterone) as well as the dosage.  
 A new theory reported from the latest studies refers to a ‘window 
of opportunity’ based on the ‘timing hypothesis’ of HRT in 
cardiovascular disease. 
1.2.4. Cardiovascular timing hypothesis 
The ´window of opportunity´ refers to the period when estrogen 
replacement therapy provides a favorable risk/benefit ratio for the CV 
system. This phenomenon generally occurs when HRT treatment is 
initiated before the age of 60 years or when it is taken within ten years of 
onset of menopause. This definition is supported by data accumulated 
from numerous studies reporting the time-dependent action of estrogens 
on the atherosclerosis process. A large multicenter randomized study 
called The Kronos Early Oestrogen Prevention Study (KEEPS) reported 
a neutral impact on CV risk markers such as intima-media thickness and 
coronary calcium score in women taking HRT in their early menopause 
(51). Furthermore, the Danish Osteoporosis Prevention Study, which 
included women with similar characteristics, revealed a significantly 
reduced risk of mortality, heart failure, or myocardial infarction (52). An 
even more recent study is the Early versus Late Intervention Trial with 
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Estradiol performed in 643 postmenopausal women, who were 
randomized to receive hormonal treatment, and stratified according to 
time since menopause (53). The ´early´ or less than six years since 
menopause group showed a significantly slower rate of atherosclerosis 
progression. 
 These findings support that the timeframe of HRT initiation 
influences the progression of cardiovascular disease, and is thus able to 
play a crucial role in primary prevention therapy (Figure 6). Although 
nowadays HRT is not prescribed to prevent cardiovascular events, the 
European Menopause and Andropause Society (EMAS) recommends the 
use of HRT (estrogen with or without progesterone) in women with 
climacteric symptoms due to its efficiency/safety profile within the 







into five phases, of which replication of chromosomal material (S phase 
or synthesis) and distribution of the genetic material (M phase or mitosis) 
are the two essential stages. However, the cells need prior preparation to 
face the S and M phases, the G1 phase (Gap 1) with  proteins and RNA 
synthesis, and the G2 phase (Gap 2) where the synthesized material is 
duplicated. Finally, when a cell stops proliferating it leaves the cycle and 
enters a period of rest or repose called G0 (56).  
To ensure the cycle develops correctly, equitable distribution and 
genomic integrity over the following generations an essential role is 
played by a group of cyclins and cyclin-dependent kinases (CDKs) that 






cyclin heterodimeric complexes sequentially for systematized cycle 
progression (56).   
Mammalian G1 cyclins and their associated kinases D-type 
cyclins D1/D2/D3 which bind to Cdk 4/Cdk 6, and E-type cyclins E1/E2 
which link up with Cdk2, are initiators of protein synthesis and 
RNA/DNA replication. These complexes are responsible for 
incorporating outside information from mitogen signals and driving cells 
through the G1 phase of the cycle (58). Both cyclin types (D and E) had 
long been thought essential for their function of access and advancement 
through G1 phase; nonetheless, recent work has challenged that view as 
findings from gene inactivation studies in animal models encoding all G1 
cyclins and their Cdks has shown normal animal development in their 
absence (59).  
Cyclins A and B, also called mitotic cyclins, join Cdks during the 
S, G2 and early M phases, and are necessary to enter into mitosis. 
Specifically, Cdk1 binds cyclins A and B, and Cdk2 binds cyclins A and 
E. As we mentioned above, cyclin E is responsible for DNA replication 
and centrosome duplication, whereas cyclin A supports both of these 
actions and mitosis, and cyclin B guides mitosis alone (60). Due to cyclin 
B´s inability to induce replication, and the resulting different biological 
functions of cyclin A and B, they are located in different parts of the cell 
and regulated separately, cyclin A being nuclear and cyclin B 
cytoplasmic. 
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CKIs (cyclin-dependent kinase inhibitors) are proteins that bind 
to CDKs by negatively regulating their activity. Depending on their 
structure and function, CKIs are classified into two families: a) the INK 
family (p15Ink4b, p16Ink4a, p18Ink4c, and p19Ink4d), characterized by 
multiple repetitions of ankyrin domains, and by explicitly inhibiting 
CDK4 and CDK6 kinases; b) the CIP/KIP family (p21Cip1/WAF1, 
p27Kip1 and p57Kip2), characterized by having a broad spectrum of 
inhibition, although they are more active against the CKD2 kinase than 
against the CDK4 and CDK1 kinases. They have a common amino-
terminal domain inhibitor of CDK/cyclin, and a structurally and 
functionally different carboxy-terminal domain (61). P27Kip1 is a Cip/Kip 
family member that plays a significant role in the control of cell 
sequence in diverse pathophysiological contexts. p27Kip1 levels are 
typically elevated during the G0/G1 phase and rapidly decrease via 
mitogen action, allowing the cells to enter the S phase. Among the 
mitogenic factors, certain hormones and growth factors are noteworthy. 
On the other hand, there are substantial signals that cause cellular 
quiescence by increasing the levels of p27Kip1, such as tumor growth 
factor β (TGFβ), low serum levels, interleukin-10, interferon-γ, and 
various cytostatic drugs.  
P27kip1 also has atheroprotective functions, as has been shown in 
studies with an animal models. ApoE-null mice with genetic inactivation 
Introduction 
66
of p27Kip1 exhibited accelerated development of atherogenesis. In 
addition to modulating proliferation, p27Kip1 may contribute to other 
cellular mechanisms involved in the atherogenesis, such as apoptosis, 
migration, and autophagy (57).  
Due to their relevance in the experiments conducted in this 
Doctoral Thesis, the following table summarizes the roles of cyclin A, B, 
D1, and the CKI p27Kip1 (Table 1).  
Protein Established function  
Cyclin A Control of S phase of cell cycle in 
complex with Cdk2 or Cdk1 
Cyclin B Control of M phase of cell cycle in 
complex with Cdk1 
Cyclin D1  Control of G1 phase of cell cycle in 
complex with Cdk4 or Cdk6 
P27Kip1 Inhibition of Cdk/cyclin complexes 
Table 1. Established functions of cyclins and CKI p27Kip1. 
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1.3.2 Effect of therapies on cell proliferation 
Endothelial effects are clinically significant in cardiovascular 
disease development. The effect of estradiol on the proliferation of 
endothelial cells has been previously demonstrated, as has its ability to 
exert a protective influence against apoptosis, in all stages of neo-
angiogenesis (62), (63), (64) . During the early atherosclerotic process, 
damage and removal of luminal endothelium causes arterial lesions to 
form, whose severity are proportional to the duration of endothelial 
denudation (65). Cell proliferation is maximal in the initial stages of 
intimal thickening; animal studies have thus shown cell proliferation and 
atherosclerotic plaque size to be inversely related. 
Although mature endothelial cells exhibit a meagre proliferation 
rate, during the process of re-endothelization of the denuded arteries, the 
endothelial cells can re-enter the cell cycle and undergo several 
proliferation cycles. The balance between action of angiogenic 
stimulators and inhibitors determines the dynamics of proliferation (66). 
Detailed knowledge of the cell cycle is of particular interest. 
Several studies have focused on raloxifene as a SERM capable of 
protecting against cardiovascular disease. This conclusion is based on its 
ability to regulate vital biochemical processes for cellular homeostasis. 
Raloxifene stimulates eNOS and promotes endothelial health by reducing 
ischemic damage in experimental conditions (67). Likewise, it supports 
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non-genomic production of prostacyclin which, together with nitric 
oxide, inhibits platelet aggregation dependent on vascular endothelium 
(68). Prostanoids such as PGI2 and thromboxane (TXA2) play an 
essential role in maintaining vascular homeostasis. In terms of cellular 
mobility, raloxifene significantly inhibits vascular smooth muscle cell 
migration (69). One line of research focused on studying whether 
SERMs promote cell proliferation in the same way as estradiol (70). 
Using cell cultures of endothelial cells (EC) from the vein of the 
umbilical cord, the research group demonstrated that the proliferative 
effect of raloxifene was similar to that induced by E2. This action is also 
associated with increased expression of cyclins A and B1.  
In contrast to the effects of estradiol and raloxifene on endothelial 
regrowth, the proliferative effects of BZA have not been studied to date.  
1.4 Selective estrogen receptor modulators (SERMs) 
1.4.1 The SERM family  
 Interest in the cardiovascular potential of SERMs has emerged 
out of the discordant behavior of estrogens in observational clinical 
studies and randomized placebo-controlled trials. Research has identified 
a wide new range of compounds with heterogeneous chemical structural 
characteristics capable of binding to ER, and leading to transcriptional 
activity in some tissues but not in others, depending on the ligand or the 
target tissue (22), (71), (72). Approximately 70 molecules with a 
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pharmacological profile of SERM type have been identified, many of 
them from both in vitro cell models and in vivo experiments. 
The triphenylethylene family represents the most classic 
members of the SERMs, including compounds such as tamoxifen and 
clomiphene citrate (first generation SERMs). Tamoxifen, a drug 
introduced more than 40 years ago for hormone-dependent breast cancer 
treatment, has been considered an antiestrogen for decades due to its ER 
blocking action in neoplastic breast cells (73). However, several 
subsequent studies suggested functional tamoxifen agonist activity in 
bone, serum lipids, and endometrium (74), (75). This, together with 
recent insights into how this medicine can modify gene expression 
according to a particular tissue, has led researchers to develop new 
compounds with potentially improved safety profiles, such as toremifene, 
ospemifene, miproxifene, droloxifene, idoxifen and other second and 
third generation SERMs (76). Toremifene has a similar pharmacological 
and clinical profile to tamoxifen. It also has antitumor activity in 
mammary carcinoma, with an estrogenic effect on the uterus and bone. It 
could probably be prescribed as a second-line agent in cases of resistance 
to tamoxifen since it has shown cross-resistance with it in resistant 
mammary tumors (77).   
 Soon after this initial finding, other antiestrogens were found to 
exhibit similar mixed functional activities, although not necessarily 
identical to each other. One example is raloxifene (previously called 
keoxifene and LY 156758), the SERM that ranks second in accumulating 
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most clinical information belonging to the benzothiophene family. 
Raloxifene was initially developed to function as a breast cancer 
treatment, but its clinical development was subsequently focused on 
prevention and treatment of postmenopausal osteoporosis, becoming the 
first SERM approved to prevent and treat this metabolic bone disorder 
(78). Evidence has accumulated supporting an agonist role for raloxifene 
in the vascular tree, and it has also been investigated for primary and 
secondary prevention of cardiovascular disease in postmenopausal 
women, and prevention of breast cancer in high-risk women, with similar 
efficacy to tamoxifen (79), (80), (81).  
Arzoxifene, a new and more potent raloxifene analog, effectively 
suppresses the growth of breast cancer cells in vitro, with agonist effects 
on the liver and bone, and antiestrogenic effects on the endometrium 
(82). As with the other new SERMs, there is little experience of clinical 
use and it is currently being studied as an anti-osteoporotic drug (83). 
 The naphthalene family includes lasofoxifene and trioxifene. The 
first mentioned is of recent development and demonstrates excellent 
SERM-like properties in animal models in vivo, showing a binding 
affinity to ERα similar to estradiol, and approximately tenfold higher 
than other SERMs, including tamoxifen and raloxifene (84). The 
lasofoxifene molecule was investigated for prevention and treatment in 
two significant areas of menopause, bone and breast, but was not 
approved by the US Food and Drug Administration owing to a slight 
increase in endometrial thickness observed (85).  
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The SERMs belonging to the benzopyran group include several 
compounds designed primarily as agents to treat hormone-dependent 
breast cancer and endometrial cancer, some of which are in the early 
stages of clinical development. The benzopyran ormeloxifene has long 
been used in India as an oral contraceptive, while levormeloxifene is its 
active enantiomer whose development has been discontinued due to its 
association with increased uterine prolapse and urinary incontinence 
(86).  
Finally, pipendioxifene and bazedoxifene are indole derivatives 
and their main representatives. Pipendioxifene is an interesting option 
under investigation as an agent with the potential to control proliferation 
in breast cancer tumor lines resistant to tamoxifen, without stimulating 
the endometrium (87). Bazedoxifene is a new drug recently approved for 
the treatment of postmenopausal osteoporosis (88). This new SERM will 
be discussed in detail in the following sections. 
Other SERMs are being developed to prevent and treat 
osteoporosis, breast cancer and cardiovascular diseases, such as MDL 
101,986, SR16234, tetrahydroisoquinoline derivatives, and 2-
phenylspiroinden. These new drugs in development should ideally 
present a neutral profile regarding side effects such as hot flushes or 
venous thromboembolic disease, the main side effects of raloxifene, 
tamoxifen and bazedoxifene,  also similar to those reported with use of 
ET/HRT and oral contraceptives. The molecular mechanism that sustains 





The ability of SERMs to induce their effects reproduce the 
molecular mechanisms of estradiol, and when they bind to intracellular 
receptors, there is a recruitment of specific proteins functionally divided 
into two opposed classes: coactivators, which activate transcriptional 
events, and in contrast, corepressors which repress them.  Several studies 
have confirmed that the ER does not remain in a stable ´on/off´ 
conformation inside the cell, but changes its structure depending on the 
essence of the bound ligand, becoming a specific three-dimensional 
conformation that determines a wide range of specific actions (89).  
In summary, the estrogen receptor is a crucial point of 
convergence of multiple signals. The unique characteristics of SERMs 
are determined by their various synthesis methods and the relative 





tissue (78).  In cellular and animal models, raloxifene has shown a 
protective effect over the endothelium in a similar magnitude to 
estrogens, avoiding the onset and progression of atherosclerosis by both 
genomic and non-genomic mechanisms. The studies observed that 
raloxifene directly and rapidly induces production of vasoactive 
substances like nitric oxide and nitric oxide synthase, important 
molecules due to their anti-inflammatory and antiatherogenic effects 
(67), (90) . Further, in vitro experiments have proved that the classical 
genomic pathways are involved after observing the activation of protein 
and gene expression of cyclooxygenase-1 and -2, leading to prostacyclin 
production, which is also antiaggregant and a vasodilatory mediator (68), 
(91). The capacity of raloxifene to promote proliferation of human 
endothelial cells in a magnitude similar to estradiol was also 
demonstrated (70). 
 Not only in experimental studies, the cardioprotective effect of 
raloxifene has been corroborated by some animal models, where 
endothelium-dependent vasodilatation was observed in coronary arteries 
of ovariectomized rats and ewes (92). Despite these beneficial findings, 
various adverse effects have been found for raloxifene in 
postmenopausal women. For example, the Raloxifene Use for the Heart 
(RUTH) study reported no benefit for coronary heart disease in 
postmenopausal high-risk women over 60 years, even showing an 
increased risk of venous thromboembolism and fatal stroke in this group 
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(80). Raloxifene could also be associated with epithelial proliferation in 
the endometrium when it is accompanied by estrogens (93).  
In order to avoid these deleterious effects, recent research has 
developed a new third-generation SERM, acetate of bazedoxifene, which 
can be used to prevent and treat postmenopausal osteoporosis with 
similar efficacy to raloxifene, but with overwhelmingly positive effects 
on endometrial thickness (94). Furthermore, bazedoxifene decreases 
estrogen-dependent proliferation rate in uterus and breast tissues due to 
its capacity to bind competitively to ER (95).  
1.5 New proposal: bazedoxifene and derivatives 
1.5.1 Bazedoxifene: SERM with improved selectivity 
Bazedoxifene acetate is a third-generation SERM approved for 
the treatment of postmenopausal osteoporosis in women at increased risk 
of fracture (96).  
This compound is capable of a significant translational impact; its 
profile has therefore improved compared to its predecessors. Its chemical 
structure is characterized by having two indoles, each with a phenyl ring, 
which serve as a specific binding site to the ER. This indole derivative is 
capable of a significant translational impact. This rigorously selected 
affinity of the ligand causes the compound to act as an agonist in tissues 
such as bone and the cardiovascular system and as an antagonistic agent 
in the uterus and breast, in addition to the particularity of being able to 
vary the spectrum of action depending on the levels of estradiol. In other 
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words, in a hyper estrogenic environment the bazedoxifene molecule acts 
as an estradiol inhibitor and has an antagonistic effect (97).  
 In the evaluation of any member of the SERM family the primary 
objective is maintaining bone mass; however, it is essentially important 
to ensure mammary and endometrial security. In initial studies performed 
in ovariectomized rat models, it has been shown to bind the estrogen 
receptor with high affinity, being able to increase bone mineral density 
and bone strength while reducing raloxifene-induced uterine cell 
hypertrophy (98).  
Its efficacy has been evaluated in randomized studies, 
demonstrating that it is effective in preventing bone loss and reducing the 
risk of postmenopausal vertebral fractures compared to placebo. Long-
term treatment with bazedoxifene has proven safety, as adverse outcome 
rates in the endometrium, breast and reproductive tract are low and 
similar to placebo (99). In the cardiovascular system, bazedoxifene 
treatment has shown to be safe and well tolerated with no increase in the 
risk of ischemic cardiac disorders or stroke across 3, 5 and 7 years of use, 
which signifies an advantage over raloxifene. However, it still presents 
an increased risk of venous thromboembolic events when compared to 
placebo in long-term administration for the treatment of osteoporosis, 
meaning women with established menopause (100), (101). The changes 
evidenced at the lipid level were beneficial, both a significant decrease in 
total cholesterol and LDL cholesterol and an increase in HDL cholesterol 
(102), (103). 
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Over the past decades, with the aim of improving the profile of 
SERMs on quality of life of postmenopausal women, different 
combinations of SERMs with estrogens have been developed, called 
tissue selective estrogen complex. 
1.5.2 Tissue-selective estrogen complex (TSEC) 
While conjugated estrogens are agonists of both α and β estrogen 
receptors, SERMs have tissue-specific estrogenic/anti-estrogenic effects. 
Laboratory studies have demonstrated distinct gene expression profiles 
compared with their individual components. The combination maintains 
the benefits of estrogens without the stimulatory effects on the breast and 
uterus, improving tolerability. 
As no SERM have demonstrated to manage menopausal 
symptoms such as vasomotor ones, indeed tend to worsen them, and 
owing to concerns about estrogen/progestin therapy revealed in the 
Women´s Health Initiative (WHI) study, TSEC has been put forward as a 
possible solution to this problem. This allows the possibility to omit 
progestin for endometrial protection and simultaneously offers 
improvement in vasomotor symptoms and protects against breast cancer 
and postmenopausal fractures. These effects have been demonstrated in 
several studies, such as in the Selective estrogen, Menopause and 
Response to Therapy (SMART) trials. 
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The first TSEC in clinical development, recently commercialized, 
combines bazedoxifene with conjugated equine estrogens (CEEs) (104). 
BZA was selected for its pharmacological profile, particularly its 
antagonistic capacity at the endometrial and mammary levels, as 
demonstrated by preclinical studies with other molecules of the SERM 





optimal pharmacological option, preclinical studies have shown that they 
are suitable for pairing with bazedoxifene (108). Another combination, 
estradiol with raloxifene, was studied without favorable results due to 
signs of endometrial stimulation observed in the treated group compared 
with placebo (109). 
To evaluate the efficacy and safety of BZA/CEE, clinical studies 
were carried out worldwide in more than 7,500 women. A formula 
combining 20 mg bazedoxifene and 0.45 or 0.625 mg conjugated 
estrogens has been approved by the FDA and the European Medicines 
Agency for endometrial safety. 
The effects of this therapy on the cardiovascular system have yet 
to be clearly defined. The SMART trials, which included healthy 
postmenopausal women aged 40-75 years, reported no increased 
incidence of adverse cardiovascular events nor venous thromboembolic 
events (VTE) compared to placebo. 
In the SMART-1 trial, performed over two years, incidence of 
VTEs was similar in both treatment and placebo groups (110). However, 
the risk is expected to be similar with bazedoxifene alone or low doses of 
estrogens, with no additive effect when administered together, which 
means an increased risk of VTEs. These effects may be related to the 
younger age of participants in the SMART trials. Moreover, this trial 
showed favorable effects on plasma concentrations of specific 
coagulation variables and inflammatory markers which have been 
associated with increased risk of CVD (111).  
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The SMART-5 trial found an improvement in lipid profiles, with 
decreased levels of total cholesterol and low-density lipoproteins, and 
increased levels of high-density lipoproteins. This study also shows 
stable levels of triglycerides, while the SMART-1 trial found an increase 
compared to placebo. 
Clinical trials involving the use of BZA alone and conjugated 
estrogens plus BZA have shown cardiovascular safety in healthy 
postmenopausal women. Nevertheless, a research group working with an 
atherosclerotic animal model identified the first potential limitations of 
BZA. Specifically, BZA therapeutic application alone did not affect 
atherosclerosis, body weight, adiposity, fasting glucose, or plasma lipid 
profile in surgically postmenopausal cynomolgus monkeys treated with 
BZA and BZA/CEE over two years. Moreover, BZA completely 
impeded the antiatherosclerotic effects of estrogen treatment in coronary 
and common iliac arteries (112). Although this study could represent a 
setback in the applicability of BZA or TSEC to maintain cardiovascular 
health in postmenopausal women, further evidence and additional studies 
are needed before establishing conclusions. Furthermore, TSEC effects 
have not been tested in women with CV disease, history of previous 
VTE, renal disease, obesity or age over 75 years, so this therapy should 
not be used in these groups. Additionally, as its effects remain unclear, 
the personal risk of cardiovascular events in long-term treatments with 




We have developed our research amid this passionate 
controversy, trying to deepen our understanding of the effects of BZA 
alone or in combination with estrogens on endothelial health through 
vascular cell proliferation in an in vitro model. The zeal of this project 
comes about because the timing hypothesis has renewed interest in 
determining the actions of drugs at early postmenopause, when the 
endothelial impact may be relevant. Moreover, SERMs are being 
reconsidered as crucial drugs in the treatment of osteoporosis in younger 
women, due to problems with long-term use of bisphosphonates. 
2. HYPOTHESIS AND OBJECTIVES
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The current hypothesis of our investigation is that new selective 
estrogen receptor modulator bazedoxifene, alone or in combination with 
estradiol, promotes the proliferation of endothelial cells in an in vitro 
model, which is associated with increased gene and protein expression in 
certain regulatory molecules of the cell cycle. We also would like to 
throw light on bazedoxifene’s impact on the cardiovascular system by 
promoting endothelium anatomical and functional integrity, a pivotal 
factor in the initiation of the atherosclerosis process. 
As the main objective, this Doctoral Thesis aims to evaluate the 
effect of bazedoxifene on human umbilical arterial endothelial cell 
(HUAEC) proliferation, and to determinate the genetic behavior of the 
main regulatory molecules of the cell cycle such as cyclin A, B, D1 and 
the inhibitory protein p27Kip1 in both fresh and cryopreserved endothelial 
cells, seeking to clarify the role of this treatment in the early stages of the 
atherosclerosis process.  
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Specific objectives: 
1. To determine if bazedoxifene promotes HUAEC proliferation in a
magnitude similar to estradiol, raloxifene, and estradiol and
bazedoxifene combined.
2. To evaluate whether this action is associated with increased
protein and gene expression in some primary cell cycle regulators
like cyclins A, B, and D1 or cell cycle inhibitor p27kip1.
3. To compare fresh and cryopreserved status of human culture
endothelial cells by characterizing their protein and gene
expression after drug application.
4. If proliferation is increased, to characterize whether it improves
endothelial repair mechanisms that would result in a protective
effect against cardiovascular disease.




3.1 Experimental design 
Primary HUAECs were isolated from nine umbilical arteries at the 
time of delivery and subcultured in vitro to determine their ability to 
proliferate and modulate cell cycle genes at the mRNA and protein level 
when exposed to different concentrations/combinations of the hormonal 
treatments being assayed.  
The nine primary cultures of endothelial cells were subcultured up 
to three times. A proportion of endothelial cells obtained from the first 
three cords were resuspended in freezing medium at -80ºC for a 3 to 3.5-
month-time span. Fresh, subcultured arterial endothelial cells were used 
to determinate their ability to proliferate after treatment application. 
Fresh and cryopreserved subcultured arterial endothelial cells were used 
to study the protein and gene expression of certain molecules of the cell 
cycle after treatment application.  
The treatments and the dose used for cell proliferation, protein and 
gene expression measurement were obtained based on binding affinity 
(EC50) of ligands to their ERα, as described elsewhere (98). Doses of E2 
and BZA in combination were half the EC50 of each compound. 
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- E2 (Sigma, Alcobendas, Spain): 3.2 nM  
- BZA (Sigma-Aldrich): 26 nM  
- RLX (Sigma-Aldrich): 2.4 nM 
- E2 + BZA (Sigma-Aldrich): 1.6 nM + 13 nM 
For experimental purposes, cells were made quiescent, and their cell-
cycle activities were synchronized at the G0 and G1 phase by the 
incubation of confluent monolayers (approximately 80%) with steroid-
deprived FBS medium for 24 hours previous to testing the experimental 
conditions of interest. 
3.2 Isolation and culture of endothelial cells 
3.2.1 Collection and primary culture 
The endothelial cells were obtained from human umbilical cord 
arteries collected from maternity wards at the time of birth, without 
differentiating between delivery methods. For this, cords were chosen 
from non-diabetic, non-smoking (or less than 15 cigarettes per day) 
mothers without cardiovascular problems or infections (hepatitis, HIV, 
etc.). Exclusion criteria were births with obstetric complication or 
intrapartum fetal distress. The cord of each new-born was double-
clamped immediately after delivery to obtain at least 15-20 cm of sample 
without knots or punctures, the rest being typically used for gasometry 
and pH determination. Although the cord is a sterile structure during 
intrauterine life, it could be contaminated during passage, so exhaustive 
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lavage was performed on the surgical area. Additionally, cold 
physiological saline under pressure was injected into the umbilical artery 
to wash it properly. The ends were surgically sectioned to simplify their 
cannulation.  
The cord was quickly placed in a sterile container and taken to 
the laboratory, where it can remain refrigerated at 4ºC for up to 24 hours, 
although our samples all were processed within 8 hours from collection 
of the material. Once in the laboratory and under sterile conditions 
(gloves, mask, surgical material and laminar flow chamber), both ends of 
the cord were cannulated with a fragment of serum system or probe in 
order to inject solution directly into the artery from the pipette. Holding 
the cord at its ends, the wall of the vein was carefully cut to expose the 
arteries and introduce a catheter inside. Once inside, it was first washed 
abundantly using at least 50 ml of PBS (Phosphate Buffered Saline, 
Gibco®, Thermo Fisher Scientific) to eliminate the remnants of blood 
that could have remained in the interior, and was checked for 
perforations. This procedure was repeated 2-3 times. The PBS was then 
removed with a pipette filled with air and the vessel lumen was filled up 
with 0.1% collagenase type I adjusted to a pH of 7.4, closing both ends 
of the cord with ring forceps. The result was incubated at the optimum 
temperature to separate the endothelial cells from the basement 
membrane without damaging them, at 37 °C for 15 minutes. Immediately 
afterwards the contents were collected in 10 ml conical tubes to 
centrifuge at 800 rpm at room temperature for 5 minutes. After this time, 
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and once the supernatant was eliminated, the cell pellet was re-deposited 
in 5 ml of M199 with phenol red (Medium 199, Earles&HEPES, 
Gibco®, Thermo Fisher Scientific). The prepared volume was seeded in 
culture flasks and finally, M199 was added as necessary up to a final 
volume of 5 ml for bottles of 25cm2 or 13-15 ml for bottles of 75 cm2 , 
and was incubated at 37ºC in 5% CO2 atmosphere. The pH of the 
medium should be maintained optimum for the adequate growth and 
multiplicity of endothelial cells.  
 
 
Figure 12. Representation of cannulated cord with serum system inserted 





Impact of bazedoxifene on endothelial health markers 
95
3.2.2 Subcultures and cell processing 
The first renewed culture took place the next day and attempts 
were made to eliminate the collagenase that might be retained. The 
successive renovations were carried out every 72 hours until the 
monolayer of cells reached semiconfluence, occupying approximately 
75% of the surface of the dish. When this happened, the surface of the 
plate was washed 2-3 times with 5 ml of PBS to remove any remains of 
the medium, then a small amount (1.5 ml) of trypsin was added and the 
resulting solution was incubated for 3 minutes at 37 °C. Immediately 
afterwards, 5 ml of M199 was administered to suppress the effect of the 
enzyme and the contents were transferred into a conical tube which was 
centrifuged at 900 rpm for 10 minutes at 25 °C to completely remove the 
trypsin. 
The obtained cellular precipitate was re-suspended in new 
medium 199 with 20% SFB (Fetal Bovine Serum, Gibco®, Thermo 
Fisher Scientific). The cell count was carried out by the dilution method 
with Trypan blue over a Neubauer chamber, following the protocol 
detailed in Appendix 1. Then they were seeded in microanalysis grids 
and in new Falcons roughly 500.000 to 1.000.000 cells per culture flask. 
A proportion of endothelial cells obtained from the first three cords were 
cryopreserved at -80ºC with Dimethyl Sulfoxide-based (DMSO) as 
described in Appendix 2.  
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The procedure by which the first subcultures were obtained, once 
in the culture flasks  and reaching the phase of semiconfluence, was also 
repeated twice, obtaining second and third subcultures. We collected and 
processed a total of fifteen umbilical cords. Cells from six cords have 
been eliminated for different reasons: one due to contamination, one due 
to lack of adhesion and four to weak growth in falcons. 
 
Figure 13. Culture process of human umbilical arterial endothelial cells 
(HUAEC). Primary culture (A) and subcultures (B) of endothelial cells in 
medium 199. 
 
3.3 Measurement of cell proliferation (XTT assay) 
The freshly prepared cells from passage 3 were seeded onto 96-
well plates at 1 x 104 cells per well. The relationship between dosage and 
effect was tested over the pharmacological concentration range of 10-1 to 
10+1 of EC50 of each compound (Table 2).  
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Equivalent comparisons were treatments 1-4 (at equal doses). 
Procedure 5 resulted from the duplication of treatment 4 doses and 
pursued the goal of exploring whether two drugs given in combination 
might have a super-additive (synergistic) effect; specifically, if the action 
was above what is expected from their individual potencies and 
efficacies. 
Treatment Dose 1 Dose 2 Dose 3 
1. E2         0.32 nM           3.2 nM          32 nM 
2. BZA          2.6 nM           26 nM    260 nM 
3. RLX         0.24 nM           2.4 nM     24 nM 
4. E2+BZA 0.16 nM E2 
+ 
1.3 nM BZA 
1.6 nM E2 
+ 
13 nM BZA 
16 nM E2 
+ 
1130 nM BZA 
5. E2+BZA-2 0.32 nM E2 
+ 
2.6 nM BZA 
3.2 nM E2 
+ 
26 nM BZA 
32 nM E2 
+ 
260nM BZA 
Table 2. Doses of different treatments used for HUAEC proliferation in XTT 
assay.  
 The cells were exposed to increasing doses of the above-
mentioned drugs and were allowed to proliferate at 37ºC with 5% CO2 
for 24 hours. After the incubation period, 50 µl of XTT mixture was 
added to each well to obtain a final desired concentration of 0.3 mg/ml. 
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The plate was incubated at 37 °C with 5% CO2 for 24 hours. The 
enzymes of metabolically active cells reduce the tetrazolium salt XTT to 
a highly colored water-soluble formazan salt. The extent of XTT 
reduction was quantified by measuring optical density at 450 nm with 
reference wavelength of 650 nm using microplate reader Wallac 1420 
Victor 2 Multilabel Reader (EG&G, Turku, Finland). 
Data are expressed as the index of formazan production by treated 
cells in comparison to formazan produced by control cells. Six technical 
replicates were analyzed in cells from three different cultures.  
 
3.4 Protein expression analysis (Western blot) 
HUAEC from passage 3 were seeded into 25 cm2 flasks and when 
70-80% of confluence was reached, culture medium was replaced with 
steroid-deprived FBS medium for 24 hours. Then, the active treatment 
with the above-mentioned concentration (section 3.1) were applied 
following by incubation period of 24 hours at 37 °C with 5% CO2.  
After that time, a 100 μl volume of lysis buffer (50 nM Tris-HCl, 
150 nM NaCl, proteinase inhibitor cocktail and phosphatase inhibitor 
cocktail adjusting to pH 7.4) was added to the samples, reaching a final 
volume of 50 ml. To achieve cell lysates, the incubation was maintained 
at 4°C under orbital agitation for 30 min. The scraping method was used 
to lift and collect the cellular debris from the culture plate surface. To 
remove the remnants from the membranes, the extracts were centrifuged 
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at 16100 rpm for 15 min at 4°C. The total protein concentration into 
lysate supernatant was measured by Pierce Micro BCA Assay (Thermo 
Fisher Scientific) and samples were frozen at −80°C until assay. The 
proteins of each sample (20 μg) were separated by 12% of SDS-PAGE 
gels (SDS-PAGE; Sodium Dodecyl Sulfate Polyacrylamide Gel 
Electrophoresis, Bio-Rad, USA) and the protein was transferred to PVDF 
membrane (Transblot Turbo Transfer pack, Bio-Rad, USA). To confirm 
that the transfer was complete, the gel was included in staining solution 
containing Coomassie Blue with 10% acetic acid and 25% methanol for 
2 hours at room temperature, visualizing proteins as blue bands on a 
clear background. Likewise, to verify that proteins had been transferred 
to the membrane, we used the aqueous Ponceau red solution, whose red 
staining could be reversibly visualized in the presence of proteins. 
 Immunostaining was achieved with specific antibodies against the 
proteins represented in Table 3 below.  
Table 3. List of specific antibodies used for immunostaining. 
 Specific antibodies for immunostaining 
Antibody name and units        Host                        Supplier 
1/500 anti-cyclin A (sc-751) rabbit 
1/200 anti-cyclin B (sc-751) rabbit 
1/200 anti-p27Kip1 (sc-1641) mouse 
1/25 anti-cyclin D1         mouse 
(NCL-cyclin D1-GM)     
Santa Cruz 
Biotechnology, 
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Blots were blocked in 5 % bovine serum albumin (BSA) and 
visualization of positive antibody binding was performed with alkaline-
phosphatase-linked anti-rabbit antibody (for cyclin A and cyclin B) or 
anti-mouse antibody (for cyclin D1 and p27Kip1), both from Sigma, 
Alcobendas, Spain. Concurrently, the membranes were re-probed with 
anti-actin antibody (Sigma, Alcobendas, Spain) to verify equivalent 
amounts of loaded protein and transfer efficiency. Finally, 
immunodetection of protein bands was visualized using 
chemiluminescence films (ImageQuantLAS4000, GE Healthcare Bio-
Sciences) and the NIH ImageJ Software performed the densitometric 
analysis.  
Data are expressed as a ratio of each protein band relative to the 
lane’s loading control (β-actin band). Three technical replicates were 
performed in cells from six cultures with different previous 
cryopreservation status (cells from three frozen and three fresh cultures).  
 
3.5 Gene expression analysis 
To evaluate the effect of drugs (E2, BZA, RLX, E2+BZA) on 
gene expression of human cell cycle markers (cyclin A, cyclin B, cyclin 
D1 and inhibitor p27kip1) the samples were treated with the same doses as 




Impact of bazedoxifene on endothelial health markers 
101
3.5.1. RNA extraction 
To assess the effect of different drugs on gene expression, total 
cellular RNA from HUAECs was extracted using the TRIzol reagent 
(Thermo Fisher Scientific®), a monophasic phenol and guanidine 
isocyanate solution capable of decomposing the stability of the cell while 
maintaining the integrity of its RNA. The procedure was carried out 
according to the manufacturer’s instructions of the original March 2013 
protocol, with slight modifications as summarized below.  
    The cells were collected in suspension after centrifugation and 
elimination of the medium, obtaining samples of 0.25 ml (5-10x106 
cells), then adding 0.75 ml of TRIzol Reagent. Once the sample was 
homogenized, it was transferred to a tube and centrifuged at 12,000 rpm 
for 10 min at 4°C and the aqueous phase, which contains the RNA, was 
transferred to a new Eppendorf tube. Samples were stored at -80°C for 
24 hours. On the second day, the samples were homogenized at room 
temperature for 5 min to re-suspend the cells and allow complete 
dissociation of the nucleoprotein complex. For each ml of extraction 
solution, 200 μl of chloroform was added, the samples were mixed in 
Vortex for 15 secs and then incubated 2-3 min at room temperature. 
After reaching that stage, the result was microcentrifuged again at 12000 
rpm for 15 min at 4ºC, and the aqueous phase was transferred to a clean 
and sterile micro tube.  
    The nucleic acids were precipitated with 500 μl of isopropanol 
100% and incubated for 10 min at -20 °C. The mixture was centrifuged 
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at maximum power for 10 min, the supernatant was removed, and 1 ml 
of ethanol 75% was added for every 1 ml of Trizol used in the initial 
homogenization. Subsequently, it was centrifuged at 7500 rpm for 5 min. 
The aqueous phase was removed.  
The RNA pellet was allowed to dry for 5-10 min at 37°C with the 
cap of the microtube open, and the pellets were re-suspended in RNase-
free water. All phases of the process were executed in RNase-free zones 
and with RNase-free solution to avoid RNA degradation. When the RNA 
was not used immediately, it was stored at -80°C until use. RNA was 
quantified by measuring absorbance spectrophotometrically at 260 nm. 
 
3.5.2. Reverse transcription  
To study specific gene expression by real-time quantitative PCR, 
the first step was RNA transcription into complementary DNA (cDNA) 
by reverse transcriptase from total RNA, carried out using the 
SuperScript First-Stand Synthesis System for RT-PCR (Invitrogen, 
Barcelona, Spain), according to the established protocol. 
One μg of RNA was mixed with 0.5 μl of a random combination 
of primers, 2 μg of an equimolar mixture of 10 mM dNTPs and RNase-
free water, reaching a final volume of 9 μg. The RNA was denatured for 
5 min at 65°C and immediately cooled to 4°C for a few minutes. 
Afterwards we added 8 μl of the 5x reaction buffer, 1 μl of 0.1 M DTT, 1 
μl of RNase Out and 1 μl of the reverse transcriptase SuperScript IV.  
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The thermal cycler was programmed with the following 
incubation times: hybridization process for 60 min at 50°C followed by 
inactivation reaction for 5 min at 85°C. The obtained cDNA samples 
were subsequently stored at -20 ° C until further study. 
3.5.3. Gene expression using Quantitative Real-Time 
PCR (QRT-PCR) 
PCR reactions were performed in real-time PCR QuantStudio5 
(Applied Biosystems, Thermo Fisher Scientific) using an SYBER Green 
PCR Master Mix (Thermo Fisher Scientific). This mixture includes the 
required amounts of deoxyribonucleotide triphosphate (dNTPs), 
AmpliTaq Gold DNA Polymerase, MgCl2, PCR buffer and SYBR Green 
fluorophore. The latter molecule, for which the product is named, has a 
distinctive characteristic: when the SYBR green fluorophore intercalates 
in double DNA helix, its increased fluorescent emission allows detection 
of the amount of DNA present in the sample without the use of specific 
probes.  
Five genes were amplified in triplicate in each sample, in 
experiments on two different days. Two microliters of total cDNA were 
amplified in a 10 μg reaction mix containing 5 μg SYBER Green PCR 
Master Mix, and 10 μM of forward and reverse primers (Table 4). 
Material and methods 
 104
Table 4. Forward and reverse primer sequences and concentrations 
corresponding to QRT-PCR amplification of cyclin A, cyclin B, cyclin D1, 
p27Kip1, and GAPDH.  
Following a 10 min Tag activation step at 95ºC, reactions were 
subjected to 40 cycles of 15 second denaturation at 95º C and 1 minute 
extension at 60ºC. In parallel, fivefold serial dilutions of well-known 
cDNA standard were run as calibration curves. To guarantee that all 
amplicons were obtained at the same temperature a melting-curve 




Cyclin A Forward 5´-TTCCCGCAATCATGTACCCTG-3´ 
Reverse 5´-TGTAGCCAGCACAACTCCACT-3´ 
10µM each 


















Expression of the genes of interest was normalized to the 
corresponding value of one of the endogenous genes (housekeeping 
gene) that show constant expression in different cellular conditions. In 
our case, we used GADPH as a housekeeping gene, and we also put 
empty wells as a negative control in each experiment.  
    The data was collected and analyzed with the QuantStudioTM 
Design & Analysis Software v.1.3.1 program (Figure 14). The cycle 
threshold (CT) is obtained when the amplification cycle signal reaches a 
level above the limit of detection.  
Data were expressed as relative quantification of gene expression 
according to the comparative Ct method (2-ΔΔCt) (113). Three technical 
replicates were performed in cells from six cultures with different 
previous cryopreservation status (cells from three frozen and three fresh 
cultures). 
Figure 14. Amplification plot of cyclins and GADPH expressions. 
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3.6 Statistical analysis  
Data analysis was performed using Generalized Estimating 
Equations (GEE) models. Variables were arranged in a hierarchical 
three-level structure to adjust standard errors for potential correlation 
between experiments whose levels of the three variables considered in 
these hierarchical models were the same (114). To analyze the effect of 
“cell treatment” on HUAEC proliferation in each one of the four doses, 
“number of replicates” was clustered within “cell treatment”, and this 
variable within “number of HUAEC cultures”. In contrast, to analyze the 
effect of “dose” on HUAEC proliferation in each one of the five cell 
treatments, “number of replicates” was clustered within “dose”, and this 
variable within “number of HUAEC cultures”. To analyze the effect of 
cell treatment on gene expression, “time of HUAEC proliferation before 
gene expression analysis” was clustered within “cell treatment”, and this 
variable within “number of HUAEC cultures”. The independent effect of 
“HUAEC cryopreservation”, i.e. whether or not HUAEC were 
cryopreserved, was also included in this particular GEE model. Finally, 
to analyze the effect of cell treatment on protein expression, “number of 
replicates” was clustered within “cell treatment”, and this variable within 
“number of HUAEC cultures”. The independent effect of “HUAEC 
cryopreservation” was included in this hierarchical GEE model. 
However, as all the cell cultures were exposed to the same “timespan of 
cell proliferation before protein-expression analysis”, this variable was 
not considered in the GEE model. 
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A NORMAL response and IDENTITY function were chosen as 
the MODEL distribution and the LINK function, respectively. The 
ROBUST variance estimator (a.k.a. the Huber/White/sandwich 
estimator) was the method used for computing the variance-covariance 
matrix of the regression parameter coefficients. The sequential Sidak test 
was used to adjust the significance level for post hoc pairwise multiple 
comparisons. Finally, the goodness-of-fit Quasi-likelihood under 
Independence Model Criterion (QIC) was used to choose among several 
working correlation structures: INDEPENDENT, EXCHANGEABLE 
and UNSTRUCTURED. The working correlation structure that had the 
smallest QIC was considered as the matrix providing the best goodness 
of fit. 
Values shown in the text and tables are estimated marginal means 
± standard error of the means (SEMs). In the figures, values are 
exponentiated regression coefficients with 95% confidence interval (CI). 
Because the dependent variables are continuous and the independent 
variables are categorical, exponentiated regression coefficients indicate 
the expected/estimated relative change in value of the dependent variable 
for a particular category of the independent variable compared to the 
reference category. When using exponentiated regression coefficients, 
results are significant when their respective 95% CI does not include 1. 
A value <1 means that the factor is negatively associated with the 
outcome. The percentage decrease in the value of the dependent variable 
is (1 - exponentiated regression coefficient) × 100.  
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Conversely, a value >1 denotes that the factor is positively 
associated with the outcome. In this case, the percentage increase in the 
value of the dependent variable is (exponentiated regression coefficient - 
1) × 100 (115). P-value<0.05. All the statistical analysis was carried out 
using the Statistical Package for Social Sciences (IBM SPSS Statistics, 
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4.1 Effect of cell treatment, number of replicates, and dose on 
HUAEC proliferation.  
Table 5 shows that cell treatment had a significant (P ≤ 0.0005) 
effect on HUAEC proliferation, irrespective of the doses used in each 
treatment. The “number of replicates” variable was also a significant (P ≤ 
0.0005) factor. 
Table 5. Overall effect of cell treatment and number of replicates on 
HUAEC proliferation.  
Dependent variable Independent variable N     P-value  
HUAEC proliferation Treatment 52 0.0005 
Number of replicates 52 0.0005 
HUAEC were exposed to increasing doses in each of the four 
treatments (E2, BZA, RLX, E2+BZA) during a 24-hour time span. Table 
6 shows the marginal means ± SEMs of data stratified by the different 
treatments and doses used in these experiments; Figure 15 presents the 
relative changes in HUAEC proliferation of these marginal means 
compared to the control untreated group, used as the reference group in 
the GEE analyses. Figure 15 indicates that at dose 1, E2 (P ≤ 0.0005), 
BZA (P ≤ 0.021), and RLX (P ≤ 0.0005) treatment displayed 
significantly higher relative values of HUAEC proliferation than the 
control group. At dose 2, a positive significant relative change in 
proliferation was also observed after cell treatment with E2 (P ≤ 0.001), 
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BZA (P ≤ 0.0005), and RLX (P ≤ 0.001) versus control values. At dose 
3, as in previous doses, increase in HUAEC proliferation was obtained 
after E2 (P ≤ 0.005), BZA (P ≤ 0.0005), and RLX (P ≤ 0.036) treatment 
when compared with control. 
Table 6. Effect of cell treatment on HUAEC proliferation at doses 1, 2 





Dose 1 Dose 2  Dose 3  
Control 0.09 ± 0.016a 0.10 ± 0.018 d 0.14 ± 0.011f 
E2 0.12 ± 0.007b 0.16 ± 0.001e 0.17 ± 0.005  
BZA 0.13 ± 0.005  0.15 ± 0.001  0.20 ± 0.009  
RLX 0.18 ± 0.001c 0.15 ± 0.006  0.18 ± 0.011  
E2+BZA 0.13 ± 0.007 0.10 ± 0.016 0.11 ± 0.019g 
a Data are estimated marginal means ± SEMs.  
b Value significantly different from the control group (P ≤ 0.002). 
c Value significantly different from the control (P ≤ 0.0005), E2 (P ≤ 0.0005), 
BZA (P ≤ 0.0005), and E2+BZA (P ≤ 0.0005) group. 
d Value significantly different from the E2 (P ≤ 0.008), BZA (P ≤ 0.0005), and 
RLX (P ≤ 0.007) group. 
e Value significantly different from the E2+BZA group (P ≤ 0.006). 
f Value significantly different from the E2 (P ≤ 0.022) and BZA (P ≤ 0.0005) 
group. 
g Value significantly different from the E2 (P ≤ 0.019), BZA (P ≤ 0.019), and 
RLX (P ≤ 0.0005) group. 
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Figure 15. Estimated relative change in HUAEC proliferation after E2, 
BZA, RLX, and E2+BZA treatment at dose 1(A), dose 2 (B), and dose 3 
(C).  
Error bars are 95% CIs.  







Error bars are 95% CIs.  
a,b,c Values significantly different to the control group (aP ≤ 0.001; bP ≤ 0.0005; cP ≤ 0.001). 
Error bars are 95% CIs.  
a,b,c Values significantly different to the control group (aP ≤ 0.004; bP ≤ 0.0005; cP ≤ 0.036). 
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The replicates analysis shown in Table 7 and Figure 16 shows 
slightly higher HUAEC proliferation with replicate 2 at dose 1 (P ≤ 
0.0005) and at dose 2 (P ≤ 0.009). Generally, there were no changes in 
proliferation content among the rest of the replicates at the mentioned 
doses. Nevertheless, the fluctuation in cell proliferation dependent on the 
number of replicates was noted at dose 3. In this case, replicate 3 (P ≤ 
0.003), replicate 4 (P ≤ 0.002), and replicate 5 (P ≤ 0.0005) we noted 




Table 7. Effect of number of replicates on HUAEC proliferation at doses 





Dose 1 Dose 2  Dose 3  
1 0.13 ± 0.028a 0.12 ± 0.023 0.11 ± 0.011e 
2 0.17 ± 0.026b 0.14 ± 0.021 0.12 ± 0.019  
3 0.14 ± 0.020  0.13 ± 0.018  0.13 ± 0.015  
4 0.09 ± 0.026 0.11 ± 0.013  0.22 ± 0.024f  
5 0.13 ± 0.023c  0.16 ± 0.012d 0.25 ± 0.022g 
6 0.13 ± 0.013 0.12 ± 0.015 0.11 ± 0.012 
a Data are estimated marginal means ± SEMs.  
b Value significantly different from replicate 1 (P ≤ 0.0005) and replicate 3 (P ≤ 
0.0005).  
c Value significantly different from replicate 4 (P ≤ 0.0005).  
d Value significantly different from replicate 4 (P ≤ 0.0005) and replicate 6 (P ≤ 
0.0005).  
e Value significantly different from replicate 3 (P ≤ 0.027), replicate 4 (P ≤ 
0.017), and replicate 5 (P ≤ 0.0005).  
f  Value significantly different from replicate 6 (P ≤ 0.0005). 
g Value significantly different from replicate 2 (P ≤ 0.027), replicate 3 (P ≤ 
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Figure 16. Estimated relative change in HUAEC proliferation depending 
on replicate number at dose 1 (A), dose 2 (B), and dose 3 (C). 
Error bars are 95% CIs.  







Error bars are 95% CIs.  
aValues significantly different to the replicate 1 (aP ≤ 0.009). 
Error bars are 95% CIs.  
a,b,c Values significantly different to the replicate 1 (aP ≤ 0.003; bP ≤ 0.002; cP ≤ 0.0005). 
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Table 8 shows a significant overall effect of dose on HUAEC 
proliferation, irrespective of the treatment applied. The “number of 
replicates” variable was also significant (P ≤ 0.0005) factor. 
Table 8. Overall effect of dose and number of replicates on HUAEC 
proliferation. 
Dependent variable  Independent variable N     P-value  
Cell proliferation Dose 43 0.0005 
Number of replicates 43 0.0005 
Table 9 shows the marginal means ± SEMs of data stratified by 
increasing incremental doses of four different drugs. Figure 17 represents 
their estimated relative variation compared to the control untreated 
group. Use of increasing doses of either E2 and RLX confirmed that 
significant changes in proliferation were only observed in response to 
dose 1 (P ≤ 0.0005 for E2, P ≤ 0.0005 for RLX) and dose 2 (P ≤ 0.018 
for E2, P ≤ 0.0010 for RLX). In case of BZA alone, the three incremental 
doses produced significant positive effects on HUAEC proliferation after 
24 hours (P ≤ 0.001 at dose 1, P ≤ 0.0005 at dose 2, P ≤ 0.0005 at dose 3 
vs. control values).  
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Table 9. Effect of increasing doses of E2, BZA, RLX or E2 + BZA on 
HUAEC proliferation.  
 
 
a Data are estimated marginal means ± SEMs.  
b Value significantly different from the control group (P ≤ 0.0005). 
c Value significantly different from the dose 1 (P ≤ 0.002), dose 2 (P ≤ 0.002), 
and dose 3 (P ≤ 0.0005). 
d Value significantly different from the dose 1 (P ≤ 0.0005) and dose 2 (P ≤ 
0.031).  
e Value significantly different from the dose 2 (P ≤ 0.0005) and dose 3 (P ≤ 
0.0005).  













E2 BZA RLX  E2+BZA 
Control  0.12 ± 0.028a 0.13 ± 0.029 c 0.12 ± 0.019d 0.10 ± 0.030 
Dose 1 0.15 ± 0.019b 0.19 ± 0.014  0.20 ± 0.006e  0.14 ± 0.002  
Dose 2  0.17 ± 0.009  0.18 ± 0.017  0.16 ± 0.005  0.12 ± 0.011  
Dose 3 0.14 ± 0.013  0.19 ± 0.02  0.15 ± 0.003  0.08 ± 0.022f  
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Figure 17. Estimated relative variation in HUAEC proliferation on 
increasing doses of E2 (A), BZA (B), RLX (C) or E2 + BZA (D).  
Error bars are 95% CIs.  






Error bars are 95% CIs.  
a,b,c Values significantly different to the control group (aP ≤ 0.001; bP ≤ 0.0005; cP ≤ 0.0005). 
Error bars are 95% CIs.  
a,b Values significantly different to the control group (aP ≤ 0.0005; bP ≤ 0.010). 
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The effect of number of replicates on cell proliferation after E2, 
BZA, RLX or E2 + BZA treatment is illustrated in Table 10 as the 
marginal means ± SEMs and in Figure 18 as their estimated relative 
change. There is a greater fluctuation in cell proliferation after treatment 
with BZA, experiencing a significant increase in proliferation after 
replicate 2 (P ≤ 0.017), replicate 3 (P ≤ 0.001), replicate 5 (P ≤ 0.002), 
and replicate 6 (P ≤ 0.0005). E2 treatment produced slightly higher 
significant values with replicate 2 (P ≤ 0.0005) and replicate 3 (P ≤ 
0.006), and RLX treatment only with replicate 2 (P ≤ 0.035). E2+BZA 
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did not significantly alter the HUAEC proliferation dependent on the 
replicate number. 
 
Table 10. Effect of number of replicates on HUAEC proliferation after 
E2, BZA, RLX or E2 + BZA treatment. 
 
 
a Data are estimated marginal means ± SEMs.  
b Value significantly different from replicate 1 (P ≤ 0.0005) and replicate 3 (P ≤ 
0.006).  
c Value significantly different from replicate 2 (P ≤ 0.017), replicate 3 (P ≤ 
0.01), replicate 5 (P ≤ 0.002), and replicate 6 (P ≤ 0.0005).  







E2 BZA RLX  E2+BZA 
1 0.13 ± 0.037a 0.11 ± 0.023c 0.15 ± 0.031 0.11 ± 0.032 
2 0.16 ± 0.041b 0.15 ± 0.041  0.16 ± 0.024d  0.12 ± 0.016  
3 0.15 ± 0.041  0.15 ± 0.033  0.12 ± 0.012  0.08 ± 0.012  
4 0.14 ± 0.007 
 
0.14 ± 0.001 0.18 ± 0.006 0.11 ± 0.017 
5 0.18 ± 0.008 
 
0.17 ± 0.008 0.20 ± 0.008 0.14 ± 0.019 
6 0.12 ± 0.011  0.30 ± 0.033  0.13 ± 0.013  0.10 ± 0.031  
Impact of bazedoxifene on endothelial health markers 
125
Figure 18. Estimated relative change in HUAEC proliferation depending 
on replicate numbers after cell treatment with E2 (A), BZA (B), RLX 
(C), and E2+BZA (D).  
Error bars are 95% CIs.  






Error bars are 95% CIs.  
a,b,c,dValues significantly different to the replicate 1 (aP ≤ 0.017; bP ≤ 0.001; cP ≤ 0.002; dP ≤ 0.0005). 
Error bars are 95% CIs.  
aValues significantly different to the replicate 1 (aP ≤ 0.035). 
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Focusing on our findings of the reduction in cell proliferation 
after E2+BZA treatment in comparison with individual E2 or BZA 
efficacy in equivalent doses, we performed the same proliferation XTT 
assay with a duplicate dose of E2+BZA. We found that high doses of 




Table 11. Effect on HUAEC proliferation of increasing dose of E2 and 
BZA alone and in combination, in standard dose of E2+BZA and 
duplicated dose of E2+BZA-2.  
 
a Data are estimated marginal means ± SEMs.  
b Value significantly different from the control group (P ≤ 0.0005). 
c Value significantly different from dose 1 (P ≤ 0.002), dose 2 (P ≤ 0.002), and 
dose 3 (P ≤ 0.0005). 
d Value significantly different from dose 1 (P ≤ 0.046) and dose 2 (P ≤ 0.003). 




  HUAEC proliferation 
E2 BZA E2+BZA E2+BZA-2 
Control  0.12 ± 0.028a 0.13 ± 0.029 c 0.10 ± 0.030 0.11 ± 0.027 
Dose 1 0.15 ± 0.019b 0.19 ± 0.014  0.14 ± 0.002  0.13 ± 0.018  
Dose 2  0.17 ± 0.009  0.18 ± 0.017  0.12 ± 0.011  0.08 ± 0.026e  
Dose 3 0.14 ± 0.013  0.19 ± 0.02  0.08 ± 0.022d  0.16 ± 0.033  
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Figure 19. Relative effect of dose of E2, BZA, E2 + BZA and E2+BZA-
2 on HUAEC proliferation.  
4.2 Effect of cell treatment on cyclins A, B, D1, and p27Kip1 protein 
expression.  
Western blot experiments were performed to investigate whether 
cell proliferation induced by different treatments was associated with 
changes in the protein expression of the cell-cycle regulators A, B, D1, 
and p27Kip1. Table 12 shows a significant overall effect of treatment on 
protein expression of all cyclins except cyclin D1. Number of replicates 
had no significant effect on A, B, D1, and p27Kip1 protein expression. In 
contrast, previous cryopreservation of HUAEC was a significant factor in 
A, B, and p27Kip1 protein expression only.   
Error bars are 95% CIs.  
a,b,c,d,eValues significantly different to the control group 
 (aP ≤ 0.0005; bP ≤ 0.001; cP ≤ 0.018; dP ≤ 0.0005; aP ≤ 0.0005). 
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Table 12. Overall effect of cell treatment, number of replicates, and 
previous cryporeservation of HUAEC on cyclin protein expression. 
 
Dependent 
variable   




Cell treatment 72 0.0005 
Number of replicates 72 0.369 




Cell treatment 72 0.0005 
Number of replicates 72 0.424 




Cell treatment 72 0.105 
Number of replicates 72 0.113 




Cell treatment 87 0.0005 
Number of replicates 87 0.458 
Cryopreservation of HUAEC 87 0.020 
 
First we focus on the effect of E2, BZA, RLX, and E2+BZA used 
to study possible changes in the protein content of a group of cyclins. 
Table 13 shows the marginal means ± SEMs of data stratified by the 
different treatments; Figure 20 represents the relative changes in protein 
expression of these marginal means compared to the control untreated 
group, used as the reference group.  
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In the case of cyclin A, although there was a tendency to increase 
protein expression when cells were exposed to different drugs, only E2 
treatment exhibited significantly higher relative values (P ≤ 0.002).  
Despite the overall effect of cell treatment to endothelial cells 
was significant on the cyclin B and cyclin D1 expression, the individual 
effect of each treatment did not evidence significant changes. 
Significantly increased p27Kip1 concentrations were reached after 
treatment of cells with E2 (P ≤ 0.006 vs. control values).  
Table 13. Effect of cell treatment on protein expression.  
Treatment Relative protein expression 
Cyclin A  Cyclin B  Cyclin D1  p27Kip1  
Control  0.10 ± 0.033a 0.21 ± 0.052 0.11 ± 0.027 0.17 ± 0.049 
E2 0.17 ± 0.027b  0.22 ± 0.053  0.26 ± 0.064  0.31 ± 0.018c  
BZA 0.20 ± 0.055  0.23 ± 0.113 0.19 ± 0.070  0.22 ± 0.031  
RLX 0.15 ± 0.029  0.27 ± 0.103 0.15 ± 0.063  0.21 ± 0.075  
E2+BZA 0.14 ± 0.034  0.14 ± 0.030  0.11 ± 0.066  0.21 ± 0.040  
a Data are estimated marginal means ± SEMs.  
b Value significantly different from the control group (P ≤ 0.016). 
c Value significantly different from the control group (P ≤ 0.054). 
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Figure 20. Estimated relative effect of cell treatment with E2, BZA, 
RLX or E2 + BZA on protein expression of cyclin A (A), cyclin B (B), 
cyclin D1 (C) and p27Kip1 (D).  
Error bars are 95% CIs.  
aValues significantly different to the control group (aP ≤ 0.002). 
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Error bars are 95% CIs. 
Error bars are 95% CIs. 
Results 
 134
Western blots obtained in these experiments are represented in Figure 21. 
Error bars are 95% CIs.  
aValues significantly different to the control group (aP ≤ 0.006). 
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When analyzing data of how previous cryopreservation of 
HUAEC affects the protein expression after drug application, Table 14 
and Figure 22 show a similar pattern of expression, irrespective of cell 
treatment type. This figure indicates that previously frozen cells 
displayed significantly higher relative values of protein expression of 
cyclin A (P ≤ 0.0005), cyclin B (P ≤ 0.0005), and p27Kip1 (P ≤ 0.020).  
Table 14. Effect of previous cryopreservation of HUAEC on protein 




Relative protein expression 
Cyclin A  Cyclin B  Cyclin D1  p27Kip1  
Fresh 0.03 ± 0.020a 0.07 ± 0.084 0.10 ± 0.075 0.15 ± 0.030 
Freeze  0.28 ± 0.020b  0.36 ± 0.058c  0.23 ± 0.022  0.30 ± 0.055d  
a Data are estimated marginal means ± SEMs.  
b Value significantly different from the fresh group (P ≤ 0.0005). 
c Value significantly different from the fresh group (P ≤ 0.0005). 
d Value significantly different from the fresh group (P ≤ 0.020). 
Results 
 138
Figure 22. Relative effect of previous cryopreservation status of cells on 
protein expression of cyclin A, cyclin B, cyclin D1 and p27Kip1.  
4.3 Effect of cell treatment on cyclins A, B, D1, and p27Kip 1 gene 
expression.   
Quantitative Real-Time Polymerase Chain Reaction Assay was 
performed to investigate whether cell proliferation induced by different 
treatments was associated with changes in gene expression of the cell-
cycle regulators A, B, D1, and p27Kip1. The overall output of GEE 
analysis between independent variables and gene expression of each 
cyclin is illustrated in Table 15. There were no significant changes in 
mRNA content after application of different treatment, day of experiment 
Error bars are 95% CIs.  
a,b,cValues significantly different to the fresh group 
(aP ≤ 0.0005; bP ≤ 0.0005; cP ≤ 0.020).   
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or basal condition of endothelial cells, aside from the only significant 
overall effect of cell treatment on p27Kip1.  
Table 15. Overall effect of cell treatment, day of experiment, and 
cryporeservation of HUAEC on cyclin gene expression. 
Dependent 
variable   
Independent variable N     P-value  
Cyclin A 
Cell treatment 52 0.208 
Day of experiment 52 0.462 
Cryopreservation of HUAEC 52 0.319 
Cyclin B 
Cell treatment 55 0.097 
Day of experiment 55 0.682 
Cryopreservation of HUAEC 55 0.934 
Cyclin D1 
Cell treatment 55 0.154 
Day of experiment 55 0.386 
Cryopreservation of HUAEC 55 0.143 
p27Kip1 
Cell treatment 54 0.0005 
Day of experiment 54 0.081 
Cryopreservation of HUAEC 54 0.960 
Table 16 and Figure 23 represent the relative changes in gene 
expression of data stratified by each treatment. No changes in any cyclin 
gene content were observed for any type of treatment compared to the 
untreated control cells.  
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Table 16. Effect of cell treatment on mRNA expression.  
 
Treatment Relative mRNA expression 
Cyclin A Cyclin B Cyclin D1 p27Kip1 
Control 0.31 ± 0.119a 0.95 ± 0.118 1.34 ± 0.168 1.84  ± 0.158 
E2 0.31 ± 0.164  0.87 ± 0.105 1.18 ± 0.097  1.78 ± 0.137  
BZA 0.34 ± 0.175  0.94 ± 0.113  1.16 ± 0.099 1.81 ± 0.177  
RLX 0.29 ± 0.163  0.91 ± 0.072  1.26 ± 0.105 2.03 ± 0.170  
E2+BZA 0.33 ± 0.190  0.83 ± 0.105  1.12 ± 0.107  1.93 ± 0.167  
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Figure 23. Estimated relative effect of cell treatment type on relative 
mRNA expression of cyclin A (A), cyclin B (B), cyclin D1 (C) and 
p27Kip1 (D).  






Error bars are 95% CIs.  
Error bars are 95% CIs.  
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The condition of endothelial cells, whether fresh or frozen, showed 
no significant variation in gene expression of cyclins either (Table 17, 
Figure 24).  
Error bars are 95% CIs. 
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Table 17. Effect of previous cryopreservation of HUAEC on relative 
mRNA expression of cyclin A, cyclin B, cyclin D1 and p27Kip1, 
irrespectively of cell treatment. 
HUAEC 
status 
Relative mRNA expression 
Cyclin A  Cyclin B  Cyclin D1  p27Kip1  
Fresh 0.48 ± 0.281a 0.91 ± 0.167 1.06 ± 0.122 1.89 ± 0.169 
Frozen 0.16 ± 0.145  0.89 ± 0.083  1.37 ± 0.163  1.87 ± 0.234  
a Data are estimated marginal means ± SEMs. 
Figure 24. Relative effect of previous cryopreservation status of cells on 
gene expression of cyclin A, cyclin B, cyclin D1 and p27Kip1.  
Error bars are 95% CIs. 
5. DISCUSSION
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Our investigation has focused on the endothelium level, a target 
organ able to prevent or slow down the pathogenesis of women´s 
cardiovascular disease. The early stages of menopause is a critical period 
where atheromatous lesions, which are the substrate of the disease, could 
develop. 
The increased incidence of atherosclerosis in women has been 
linked to the cessation of gonadal hormone production, although this is 
not unanimously accepted. When this happens, gynecologists initially 
lead with the effects of hypoestrogenism that occur after the interruption 
of ovarian function, and then with cardiovascular pathology after 
menopause and its hormonal treatment. This treatment initially improves 
quality of life for many women, but in the longer term promotes health 
problems such as cardiovascular function, osteoporosis and dementia. 
Recently, new drugs have been added to menopausal hormone therapy in 
the treatment spectrum for postmenopausal women, such as SERM and 
TSEC, of which we still have little information regarding cardiovascular 
dysfunction.  
There are a wide range of research topics focused on the 
atherosclerosis process. Owing to the slow progression of cardiovascular 
disease, research in humans is a quite complex process requiring a large 
number of patients and many years of follow-up to reach conclusions, 
which in epidemiological studies are often unreliable, yielding 
insufficient evidence to defend or reject hormone replacement therapy 
for this pathology. 
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This has led researchers to develop strategies for assessing 
changes in vascular endothelium at the preclinical stage. On the one 
hand, there are experimental animal models in which pathophysiology 
can be studied over a shorter time span and in a more homogeneous way. 
And on the other hand, in vitro cell culture is useful for understanding  
endothelial cell behavior, such as interaction with various mediators. The 
endothelial cells damaged after acute mechanical vessel injury or 
noxious stimuli represent a physiologic challenge that can further alter 
endothelial repair, and therefore, proliferation, gene, and protein 
expression.  
In order to gain a clearer understanding of the gap between 
clinical and basic science, we decided to concentrate on samples and 
study human endothelial tissue. For this reason, our project has focused 
on assessing how bazedoxifene, a recently incorporated therapy used in 
postmenopausal women, is able to induce the proliferation process in 
healthy human vascular endothelial cells, either alone or in combination 
with estradiol. Other estrogen-based preparations were also evaluated 
and compared with bazedoxifene. From this perspective, the method has 
allowed us to approach the early stages of the atherosclerotic process 
from an experimental point of view, providing more data pertinent to this 
treatment in prevention of cardiovascular pathology in postmenopausal 
women. 
It is important to highlight the strengths of this work, which 
contributes original research on bazedoxifene, and provides data which 
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elucidates the potential CV impact of bazedoxifene. The area of CV 
impact of SERMs has been poorly investigated following the neutral 
effects of raloxifene in the RUTH study. However, limited data exist 
concerning the impact on the initial stages of atherosclerosis, of value for 
women entering the postmenopausal period. 
5.1 Methodological considerations 
Human umbilical vein endothelial cells (HUVECs) and human 
umbilical artery endothelial cells (HUAECs) derived from human 
umbilical cord vein and artery, respectively, are the most commonly used 
cell type for the study of endothelial function and disease adaptation in 
vitro. EC culture has been considered the gold standard in cardiovascular 
research since the 1980s (116). Although both HUVEC and HUAEC are 
derived from umbilical cord, they have different functions due to their 
particular genetic and molecular background (117). Human vascular 
endothelial substance has had limited availability until recently, and the 
advances in understanding of vascular physiology have stemmed mainly 
from experiments performed with cultured ECs. For this reason, this 
technique could be considered as a helpful and convenient method, 
complementary to ex vivo methods and animal models.  
Proliferation and endothelial barrier function have been evaluated 
in vitro in several studies to assess inflammatory status in diabetes and 
atherosclerosis processes (118). These experiments were basically made 
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in HUVECs, under a specific design that precipitates the above 
mentioned pathological conditions, and the main findings were 
suppressed cell number, delayed replication, disrupted cell cycle, 
compromised endothelial barrier and accelerated death.  
In the study a research group working with hormonal therapy in 
vitro models demonstrated that both estradiol and raloxifene promote 
proliferation of HUVEC in a similar magnitude. This could suggest a 
protective response against atherogenesis, as a consequence of the major 
proliferative effect and therefore better re-endothelization capacity (70). 
However, the study was conducted in endothelial cells of venous origin, 
but no data exist on the proliferative effect on arterial endothelial cells 
after hormonal menopausal treatment. This is a matter of particular 
interest since atherosclerosis occurs in arteries, and as already discussed, 
in several genes expression profiling differs in endothelial cells from 
different blood vessels (117). 
The in vitro EC culture model has several advantages and some 
disadvantages. On the one hand, redundant cord tissue can be obtained 
easily from the umbilical cord after delivery and no further surgical 
intervention is needed for the patient. The ordinary length of human 
umbilical cord is approximately 50-55 cm, which provides sufficient 
amounts of cells to work with (119), cords of at least 15-20 cm of the 
sample being used in our work. Vascular cells are the potential source for 
isolation of three main cell types: endothelial cells, smooth muscle cells, 
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and fibroblasts. Once isolated, cells can be cryopreserved for use when 
needed. Despite the fact that thawing, reculturing, and expanding 
techniques are applied after cryopreservation, these cells showed similar 
properties regarding morphology and proliferation potential, as reported 
in previous studies (120).  
On the other hand, the in vitro fabrication process of both 
HUAEC and HUVEC for research is a complex practice which requires 
strict quality control to ensure adequate cell isolation, cell cultivation in 
terms of primary culture, and cell growth leading to the final product 
prepared for cryopreservation. Several problems may occur during the 
entire process, such as: 1. absence or few viable cells after thawing (poor 
quality of culture, microbial contamination, inappropriate freezing rate, 
etc.); 2. poor cell attachment after thawing from passaging or stock (low 
room humidity, inadequate mixing of cells, media or other reagents, 
etc.); 3. slow cell growth (cells over-passaged, lacking CO2 levels, 
fluorescent light damage, inaccurate cell counting method, etc.); 4. 
uneven cell growth (inadequate mixing of cells or media, temperature 
variations within the incubator, uneven evaporation and vibration in the 
incubator, etc.). 
The model used in our study is much more difficult to use than 
HUVEC, and we worked extraordinarily hard to improve the quality of 
the results. A total of fifteen umbilical cords were collected and 
processed, with six losses during the process: one due to contamination, 
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one due to lack of adhesion, and four due to poor growth in culture 
flasks. Fortunately, we were able to locate the exact source of the 
problem in time and correct the multiple potential causes of poor growth, 
demonstrating the importance of using standardized protocols as a basis 
for standard operating procedures, to ensure efficiency and 
reproducibility for future practice.  
Looking forward, good manufacturing practice conditions and 
guidelines have already been established for vascular umbilical cord cells 
culture, the main advantages of the current cell banks that represent an 
excellent cell source for cardiovascular tissue engineering (120).  
5.2 Effect of cell treatment, number of replicates, and dose on 
HUAEC proliferation.  
Our investigation is novel in that it shows that bazedoxifene alone 
promotes proliferation of HUAECs in a magnitude similar to estradiol 
and raloxifene.  
Most scientific evidence to date has collected information about 
estrogens and raloxifene and their ability to accelerate endothelial cell 
growth in vitro models (121), (62), (70), which is crucial for functional 
endothelial preservation. Taken together with other actions, this 
underscores the protective effect of estrogens and raloxifene against 
atherogenesis. Estradiol has been shown to induce a favorable lipid 
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profile by decreasing low-density lipoprotein levels and serum Lp (a) 
lipoprotein concentration, while increasing high-density lipoprotein 
levels (122). Raloxifene also favorably alters the lipoprotein profile to a 
similar but less pronounced degree than estrogen (123), both protecting 
low-density lipoprotein from oxidation (124), (125). The promotion of 
endothelial health is also suggested by estrogen and raloxifene 
vasodilatory effects, and more recently by the upregulation of 
atheroprotective prostacyclin throughout cyclooxygenase 1 and 2, thus 
reducing some of the adhesion molecules (126). Furthermore, estrogen 
and raloxifene exert an antiproliferative effect on smooth-muscle cells, 
contributing directly to vascular long-term protection (127).  
Bazedoxifene, the latest selective estrogen to enter the market for 
osteoporosis treatment in postmenopausal women, was placed top of a 
long list of SERMs due to its overwhelmingly positive results in relevant 
clinical trials, notwithstanding the paucity of evidence about efficacy on 
the cardiovascular system. 
Bazedoxifene alone and in combination with CEE was associated 
with a favorable lipid level profile, obtaining significant reductions in 
total and LDL cholesterol levels and significant increases in HDL 
cholesterol levels in women (110), (128)  despite producing null effect in 
monkeys (112).  
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BZA and BZA/CEE action on extent and severity of 
atherosclerosis has been investigated by only one research group, which 
focused their experiments on three arterial territories of surgically 
postmenopausal monkeys (112), (129). BZA alone had no effect on 
atherosclerosis of coronary, peripheral and cerebral arteries nor any 
change in body weight, adiposity, fasting glucose, or plasma lipid profile. 
Furthermore, they observed BZA interference in the capacity of CEE to 
prevent atherosclerotic lesions developing in coronary and peripheral 
vascular sectors, but it did not attenuate CEE’s inhibition of plaque 
complications in the common carotid artery.  
The limited current available data on bazedoxifene is via in vitro 
studies at the endothelium level. Only one research group demonstrated 
that bazedoxifene could act as an anti-inflammatory and anti-oxidative 
agent against proteins and lipids that become glycated due to exposure to 
sugars, called advanced glycation end products (AGE), and their receptor 
RAGE, using HUVECs. There is an accumulating body of evidence that 
these particles have thrombogenic and inflammatory properties on the 
endothelial cells, thereby creating a pathological link between 
complications in diabetes, accelerated atherosclerosis and vascular 
calcification (130).  
There is no information, however, on the effect of BZA alone and 
in association with estrogen compounds on endothelial cell proliferation. 
As the integrity and regeneration of endothelium seems relevant for 
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cardiovascular health, the potential effect of BZA on proliferation is of 
interest.  
Our investigation demonstrated for the first time bazedoxifene’s 
capacity to induce proliferation in endothelial cells, albeit in a modest 
quantity, but similar to the range reached by estradiol and raloxifene. 
This seems to be observation congruent since mature ECs exhibit a very 
low proliferation index (131). Moreover, a comparable effect was 
observed in the spectrum of concentration range of 10-1 to 10+1 of EC50 
of each compound. Both estradiol and raloxifene treatment showed less 
proliferation at higher concentration. We do not have a clear explanation 
regarding the decrease in effect with the increase in dose, but this 
paradoxical result was also observed in previous reports, affirming 
similar responses to estradiol and raloxifene (62), (70). Nevertheless, 
these studies were carried out in endothelial cells of human umbilical 
cord veins, but no arteries, and with different range of dosages.   
The relationship between dosage and effect on proliferation after 
the concurrent cell treatment with bazedoxifene plus estradiol did not 
yield a significant result either with a standard dose or after performing 
the same proliferation XTT assay with a duplicated dose. The only 
experimental work studying analogous correlation showed BZA 
interference in the capacity of CEE to prevent the development of 
atherosclerotic lesions in animal models (112). 
Discussion 
 156
Our investigation also took into consideration the experimental 
variation which comes from both the process and the biological source 
variability. Biological replicates were obtained using umbilical cords 
from different patients and served to provide information about the 
population. Supplementary technical replicate analysis was conducted to 
provide information about process variability and accuracy of laboratory 
measurements regarding both dose and treatment evaluation. Very slight 
variability was detected at doses 1 and 2; specifically, one of the six 
replicates showed significantly different values, whereas a little more 
fluctuation in proliferation was observed at dose 3. Likewise, the 
treatment with bazedoxifene showed modest variability, unlike estradiol, 
raloxifene, and estradiol plus bazedoxifene treatments. This observation 
may suggest that more accurate measurement is needed to test 
proliferation at dose 3 and treatment with bazedoxifene, or the need to 
include a greater number of biological samples in the analysis, since we 
cannot recognize which six technical replicates came from each 
biological replicate. 
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5.3 Effect of cell treatment on cyclins A, B, D1, and p27Kip1 protein 
and gene expression.  
In our work the proliferative effect induced by bazedoxifene, 
estradiol, raloxifene, and combination of estradiol plus bazedoxifene was 
not associated with increased gene expression of cell cycle key regulators 
such as cyclin A, cyclin B, cyclin D1 and p27Kip1. Despite this, increases 
in cyclin A and p27Kip1 protein content were detected only after treatment 
with estradiol.  
Endothelial cells, under normal conditions and especially when 
facing physiological and pathological aggression, undergo phenotypic 
modulation and re-enter the cell cycle, which is a highly complex process 
due to the larger number of proteins participating at different phases 
(131). A complex composed of CDK and the regulatory subunit cyclin 
must be activated to advance through the cell cycle, while CKI 
modulates it negatively (57). At least twenty different holoenzymes 
participate in controlling the cell cycle, of which we have studied four, 
three activators and one inhibitor. 
On cell proliferation there is a wide range of evidence regarding 
the genetic regulation with estrogenic treatment made in experiments 
with breast cancer cells, which points to the possibility that estrogen may 
share the same effect in vascular cells.  
Most work supports that E2 up-regulates cyclin A2, (70), cyclin 
B1 (70), cyclin D1 (132), (133), (134). Although it was also observed 
that long term ethinyl estradiol (EE) treatment in rats decreased levels of 
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all proteins required for a proper G1/S-transition and S phase 
progression, such cyclin A, cyclin E and CDK2 (135). This is true even 
in studies where the cyclin-associated CDK activity didn’t seem to 
depend on an increase in cyclin or CDK protein, or a decrease in CKI 
protein. 
Although only isolated data of significant increases were detected 
at some point in the curves for protein levels, the confirmation of 
proliferation draws attention to a propensity towards positive changes in 
protein content, which could probably be fully achieved by increasing 
the sample size and procedural rigor, or if other determinants of cell 
proliferation had been explored. 
Our analysis detected no significant changes in the gene 
expression of cyclins in cells treated with E2, BZA, RLX, and E2+BZA. 
The relation of these modifications to the cell cycle in endothelial arterial 
cells treated with these drugs is still unclear, since data are inconclusive. 
We do not have a clear explanation for the lack of concordance observed 
between the gene and protein expression of cyclins studied, but post-
transcriptional and post-translational modifications could be involved in 
the process of protein biosynthesis from genetic cell content, and further 
work should help in resolving this issue.  
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5.4 Effect of cryopreservation of HUAEC on cyclins protein and 
gene expression.  
Nowadays, the analysis of biological markers (DNA, RNA, and 
proteins) has become a technique capable of diagnosing disease risk, 
monitoring and establishing possible responses to potential therapies 
(136). As not all biological specimens can be processed immediately 
after collection, and since the process of transportation, storage and 
verification could require a long time, cryopreservation has become a 
widely used method over the last few decades. Hence, biobanks, where 
human biological materials are cryopreserved at -80°C or in liquid 
nitrogen, are a crucial source in the scientific research. Moreover, the 
technique of cryopreservation has produced important advances in 
gynecology, specifically for reproductive medicine, since human oocyte, 
embryos and ovarian tissue could be cryostored. For this reason, as a 
matter of interest we investigated changes in RNA and protein 
expression in arterial endothelial cells after cryopreservation at -80°C 
and in liquid nitrogen. Naturally, RNAs and proteins are much less 
unstable and exposed to faster degradation than DNA, and the 
methodology of sample collection, handling, processing and preservation 
may easily influence the diagnostic results (137).  
We found that freeze arterial endothelial cells displayed 
significant changes in protein levels for cyclin A, cyclin B and p27Kip1
compared to the fresh control sample. However, no obvious significant 
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trend was observed in RNA profile for any cyclin after freezing and 
storage. Similar observation was found in previous works showing that 
the presence of cryoprotective agents, such as DMSO we used, increased 
the survival rates of cells after cryopreservation, even though there was 
no consistent trend observed with regard to the RNA expression 
measurements (136).  
The data indicate a need for more accurate strategies for 
processing biological specimens or new solutions that could protect 
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In the light of the results obtained, the following conclusions can be 
drawn:  
- The use of bazedoxifene at increasing doses is followed by a 
moderate proliferative effect on HUAEC in an in vitro model. 
- This action was not associated with major protein and gene 
expression of key cell cycle regulators such as cyclin A, cyclin B, 
cyclin D1 and p27Kip1. Despite not finding consistency between 
cell proliferation and greater gene expression of cyclin A, cyclin 
B, cyclin D1 and p27Kip1, we suspect that other cell cycle 
regulators might be involved in the process. 
- Bazedoxifene promotes proliferation of HUAEC in a similar 
magnitude to estradiol and raloxifene.  
- There was no significant relationship between dosage and effect 
on proliferation after concurrent cell treatment with bazedoxifene 
plus estradiol.   
- The cryopreservation process displayed positive changes in 
protein content of cyclins compared to fresh endothelial cells. On 
the other hand, no obvious significant trend was observed in 
RNA profile for any cyclin after freezing and storage.
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The main strength of this Doctoral Thesis lies in the consistency 
of the model. Arterial cells from human umbilical cords have been used 
to assess endothelial function as they allow an excellent approach to the 
physiological context of the arteriosclerosis process that occurs at the 
artery level. Until now no data has been published on the proliferative 
effect on arterial endothelial cells after menopausal hormonal treatment. 
Most of our knowledge from in vitro proliferative studies comes from 
umbilical vein cell culture since these cells do not experience as much 
aging in the subcultures. Despite the difficulties experienced in obtaining 
subcultures of arterial endothelial cells, we refrained from using cell 
lines. 
Another point to highlight in the present Doctoral Thesis is the 
use of multiple technical replicates in the analysis of proliferation, 
protein and gene expression, which offered some advantages to our 
study. Among them the most notable are the evaluation of variation in 
the experiments, the  overall precision of proliferation measurements, 
and not so suitable in gene and protein expression measurements. The 
use of proper replicates analysis instead of average values allowed 
smaller changes to be detected within the sample or the experimental 
procedure.  
Although the present study represents a very limited experimental 
work, the results obtained allow us to speculate about the approach to 
understanding of the endothelial proliferative response under specific 
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hormonal treatment and the beneficial effect of bazedoxifene alone on 
endothelial disorders like atherosclerosis.  Nevertheless, the variability of 
the data indicates a need for further studies with an increased biological 
sample size. Also, there is a different mechanism by which the treatment 
of cells with drugs could enhance proliferation. Apart from the classical 
ER pathways, the ligand-independent pathway, the ERE-independent 
pathway and the nongenomic pathway are the potential alternatives, but 
we did not analyze their possible mechanisms in our work. Nor did we 
include the entire battery of cell cycle regulators involved in the cell 
growth and differentiation process.  
In this experimental work proliferation exhibited clear 
conclusions, but the door is open to a further edifying research on 
mediators and pathways, since relatively few have been studied, yielding 
a limited number of observations. In contrast, the strength of using 
HUAEC, and of exploring bazedoxifene or, even more, bazedoxifene in 
association with estradiol, has intrinsic value. The data regarding 
possible interference between estradiol and bazedoxifene when acting 
together are noteworthy  and merit further exploration. 
8. BIBLIOGRAPHY
Impact of bazedoxifene on endothelial health markers 
Impact of bazedoxifene on endothelial health markers 
171
1. Dagenais GR, Leong DP, Rangarajan S, Lanas F, Lopez-
Jaramillo P, Gupta R, et al. Variations in common diseases,
hospital admissions, and deaths in middle-aged adults in 21
countries from five continents (PURE): a prospective cohort
study. Lancet. 2019 Sep; 395(10226) 785-794.
2. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ,
Cushman M, et al. Heart disease and stroke statistics-2016 update
a report from the American Heart Association. Vol. 133,
Circulation. 2016. p. e38–48.
3. European Cardiovascular Disease Statistics 2017 edition. 2017;
4. Farin HMF, Abbasi F, Reaven GM. Body mass index and waist
circumference both contribute to differences in insulin-mediated
glucose disposal in nondiabetic adults. Am J Clin Nutr.
2006;83(1):47–51.
5. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med.
1999;340(2):115–26.
6. Yusuf PS, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, et
al. Effect of potentially modifiable risk factors associated with
myocardial infarction in 52 countries (the INTERHEART study):
Case-control study. Lancet. 2004;364(9438):937–52.
7. Rossi R, Nuzzo A, Origliani G, Modena MG. Prognostic Role of
Flow-Mediated Dilation and Cardiac Risk Factors in Post-
Menopausal Women. J Am Coll Cardiol. 2008;51(10):997–1002.
8. Schächinger V, Britten MB, Zeiher AM. Prognostic impact of
coronary vasodilator dysfunction on adverse long-term outcome of
coronary heart disease. Circulation. 2000;101(16):1899–906.
9. Matsuzawa Y, Sugiyama S, Sugamura K, Nozaki T, Ohba K,





Ischemic Heart Disease in Women. J Am Coll Cardiol. 
2010;55(16):1688–96.  
10. Harvey RE, Coffman KE, Miller VM. Women-specific factors to
consider in risk, diagnosis and treatment of cardiovascular disease
Ronée. Womens Heal (l Engl). 2015;11(2):239–57.
11. Lambrinoudaki I, Armeni E, Georgiopoulos G, Kazani M,
Kouskouni E, Creatsa M, et al. Subclinical atherosclerosis in
menopausal women with low to medium calculated cardiovascular
risk. Int J Cardiol. 2013;164(1):70–6.
12. Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. Endothelial
dysfunction as a target for prevention of cardiovascular disease.
Diabetes Care. 2009;32 Suppl 2.
13. Kannel WB, Hjortland MC, McNamara PM, Gordon T.
Menopause and risk of cardiovascular disease: the Framingham
study. Ann Intern Med. 1976;85(4):447–52.
14. Debing E, Peeters E, Duquet W, Poppe K, Velkeniers B, Van den
Brande P. Endogenous sex hormone levels in postmenopausal
women undergoing carotid artery endarterectomy. Eur J
Endocrinol. 2007;156:687–93.
15. Atsma F, Bartelink M-LEL, Grobbee DE, van der Schouw YT.
Postmenopausal status and early menopause as independent risk
factors for cardiovascular disease: a meta-analysis. Menopause.
2006;13(2):265–79.
16. Matthews KA, Crawford SL, Chae CU, Everson-Rose SA, Sowers
MF, Sternfeld B, et al. Are Changes in Cardiovascular Disease
Risk Factors in Midlife Women Due to Chronological Aging or to
the Menopausal Transition? J Am Coll Cardiol.
2009;54(25):2366–73.
Impact of bazedoxifene on endothelial health markers 
173
17. El Khoudary SR, Santoro N, Chen HY, Tepper PG, Brooks MM,
Thurston RC, et al. Trajectories of estradiol and follicle-
stimulating hormone over the menopause transition and early
markers of atherosclerosis after menopause. Eur J Prev Cardiol.
2015;23(7):694–703.
18. Montt-Guevara MM, Giretti MS, Russo E, Giannini A, Mannella
P, Genazzani AR, et al. Estetrol modulates endothelial nitric oxide
synthesis in human endothelial cells. Front Endocrinol
(Lausanne). 2015;6(JUL):111.
19. Miller VM, Duckles SUEP. Vascular Actions of Estrogens :
Functional Implications. Pharmacol Rev. 2008;60(2):210–41.
20. MacGregor JI, Jordan VC. Basic guide to the mechanisms of
antiestrogen action. Pharmacol Rev. 1998;50(2):151–96.
21. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson
JA. Cloning of a novel receptor expressed in rat prostate and
ovary. Proc Natl Acad Sci U S A. 1996;93(12):5925–30.
22. Cano  a, Hermenegildo C. Modulation of the oestrogen receptor: a
process with distinct susceptible steps. Hum Reprod Update.
2000;6(3):207–11.
23. Hodgin JB, Krege JH, Reddick RL, Korach KS, Smithies O,
Maeda N. Estrogen receptor α is a major mediator of 17β-
estradiol’s atheroprotective effects on lesion size in Apoe-/- mice.
J Clin Invest. 2001; 107(3) 333-340.
24. Lindner V, Kim SK, Karas RH, Kuiper GG, Gustafsson JA,
Mendelsohn ME. Increased expression of estrogen receptor-beta






25.  Christian RC, Liu PY, Harrington S, Ruan M, Miller VM, 
Fitzpatrick L a. Intimal estrogen receptor (ER)beta, but not 
ERalpha expression, is correlated with coronary calcification and 
atherosclerosis in pre- and postmenopausal women. J Clin 
Endocrinol Metab. 2006;91(August):2713–20.  
26.  Meyer MR, Barton M. ERα, ERβ, and gpER: Novel aspects of 
oestrogen receptor signalling in atherosclerosis. Cardiovasc Res. 
2009;83(4):605–10.  
27.  Meyer MR, Haas E, Prossnitz ER, Barton M. Non-genomic 
regulation of vascular cell function and growth by estrogen. 
Molecular and Cellular Endocrinology. 2009;308:9-16. 
28.  Björnström L, Sjöberg M. Mechanisms of estrogen receptor 
signaling: convergence of genomic and nongenomic actions on 
target genes. Mol Endocrinol. 2005;19(4):833–42.  
29.  Hammes SR, Levin ER. Extranuclear steroid receptors: Nature 
and actions. Vol. 28, Endocrine Reviews. 2007. p. 726–41.  
30.  Szego CM, Davis JS. Adenosine 3’,5’-monophosphate in rat 
uterus: acute elevation by estrogen. Proc Natl Acad Sci U S A. 
1967;58(4):1711–8.  
31.  Pietras RJ, Szego CM. Surface modifications evoked by estradiol 
and diethylstilbestrol in isolated endometrial cells: evidence from 
lectin probes and extracellular release of lysosomal protease. 
Endocrinology. 1975;97(6):1445–54.  
32.  Hisamoto K, Bender JR. Vascular cell signaling by membrane 
estrogen receptors. In: Steroids. 2005. p. 382–7.  
33.  Moriarty K, Kim KH, Bender JR. Minireview: Estrogen receptor-
mediated rapid signaling. Vol. 147, Endocrinology. 2006. p. 
5557–63.  
Impact of bazedoxifene on endothelial health markers 
175
34. Haynes MP, Sinha D, Russell KS, Collinge M, Fulton D, Morales-
Ruiz M, et al. Membrane estrogen receptor engagement activates
endothelial nitric oxide synthase via the PI3-kinase-Akt pathway
in human endothelial cells. Circ Res. 2000;87(8):677–82.
35. Simoncini T, Genazzani AR. Non-genomic actions of sex steroid
hormones. Vol. 148, European Journal of Endocrinology. 2003. p.
281–92.
36. Stefano GB, Prevot V, Beauvillain JC, Cadet P, Fimiani C,
Welters I, et al. Cell-surface estrogen receptors mediate calcium-
dependent nitric oxide release in human endothelia. Circulation.
2000;101(13):1594–7.
37. Ho KJ, Liao JK. Non-nuclear actions of estrogen: new targets for
prevention and treatment of cardiovascular disease. Mol Interv.
2002;2(4):219–28.
38. Nakajima T, Kitazawa T, Hamada E, Hazama H, Omata M,
Kurachi Y. 17beta-Estradiol inhibits the voltage-dependent L-type
Ca2+ currents in aortic smooth muscle cells. Eur J Pharmacol.
1995;294(2–3):625–35.
39. Prossnitz ER, Barton M. Estrogen biology: New insights into
GPER function and clinical opportunities. Vol. 389, Molecular
and Cellular Endocrinology. 2014. p. 71–83.
40. Lappano R, De Marco P, De Francesco EM, Chimento A, Pezzi V,
Maggiolini M. Cross-talk between GPER and growth factor
signaling. J Steroid Biochem Mol Biol. 2013;137:50–6.
41. Wehling M, Schultz A, Lösel R. Nongenomic actions of






42.  Meyer MR, Prossnitz ER, Barton M. The G protein-coupled 
estrogen receptor GPER/GPR30 as a regulator of cardiovascular 
function. Vascular Pharmacology. 2011; 55:17-25. 
43.  Newson L. Menopause and cardiovascular disease. Post Reprod 
Heal. 2018;24(1):44–9.  
44.  Manson JE, Martin KA. Postmenopausal Hormone-Replacement 
Therapy. N Engl J Med. 2001;345(1):34–40.  
45.  Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, 
Speizer FE, et al. Postmenopausal estrogen therapy and 
cardiovascular disease. Ten-year follow-up from the nurses’ health 
study. N Engl J Med. 1991;325(11):756–62.  
46.  Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, 
Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen 
plus progestin in healthy postmenopausal women: principal results 
From the Women’s Health Initiative randomized controlled trial. 
JAMA. 2002;288(3):321–33. 
47.  Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et 
al. Randomized trial of estrogen plus progestin for secondary 
prevention of coronary heart disease in postmenopausal women. 
Heart and Estrogen/progestin Replacement Study (HERS) 
Research Group. JAMA. 1998;280(7):605–13.  
48.  Anderson GL, Limacher M. Effects of Conjugated Equine 
Estrogen in Postmenopausal Women with Hysterectomy: The 
Women’s Health Initiative Randomized Controlled Trial. J Am 
Med Assoc. 2004;291:1791-1912. 
49.  Manson JAE, Chlebowski RT, Stefanick ML, Aragaki AK, 
Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and 
health outcomes during the intervention and extended 
poststopping phases of the women’s health initiative randomized 
Impact of bazedoxifene on endothelial health markers 
177
trials. Obstetrical and Gynecological Survey. 2013;310:1353-
1368. 
50. Ouyang P, Michos ED, Karas RH. Hormone Replacement
Therapy and the Cardiovascular System. Lessons Learned and
Unanswered Questions. Vol. 47, Journal of the American College
of Cardiology. 2006. p. 1741–53.
51. Harman S, Brinton E, Cedars M, Lobo R, Manson J, Merriam G,
et al. KEEPS: The Kronos Early Estrogen Prevention Study.
Climacteric. 2005;8(1):3–12.
52. Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P,
Mosekilde L, et al. Effect of hormone replacement therapy on
cardiovascular events in recently postmenopausal women:
randomised trial. BMJ. 2012;345(3):e6409.
53. Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ,
Hwang-Levine J, et al. Vascular Effects of Early versus Late
Postmenopausal Treatment with Estradiol. N Engl J Med.
2016;374(13):1221–31.
54. Armeni E, Lambrinoudaki I, Ceausu I, Depypere H, Mueck A,
Pérez-López FR, et al. Maintaining postreproductive health: A
care pathway from the European Menopause and Andropause
Society (EMAS). Maturitas. 2016;89:63–72.
55. Bolton JL. Menopausal Hormone Therapy, Age, and Chronic
Diseases: Perspectives on Statistical Trends. Vol. 29, Chemical
Research in Toxicology. 2016. p. 1583–90.
56. Norbury C, Nurse P. Animal Cell Cycles and Their Control. Annu
Rev Biochem. 1992; 61:441-70.
57. Fuster J, Ferna P, Gonza H, Silvestre C, Naim Y, Nabah A, et al.





animal models and human studies. 2010;254–64.  
58. Morgan DO. CYCLIN-DEPENDENT KINASES: Engines,
Clocks, and Microprocessors. Annu Rev Cell Dev Biol. 1997;
13:261-91.
59. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-
dependent kinases. Genes and Development. 2004;18:2699-2711.
60. Murray AW. Recycling the Cell Cycle: Cyclins Revisited. Cell.
2004 Jan 23;116(2):221-34.
61. Lim S, Kaldis P. Cdks, cyclins and CKIs: roles beyond cell cycle
regulation. Development. 2013 Aug;140(15):3079-93.
62. Lippert C, Seeger H, Mueck AO, Lippert TH. The effects of A-
ring and D-ring metabolites of estradiol on the proliferation of
vascular endothelial cells. Life Sci. 2000 Aug;67(13):1653–8.
63. Mueck AO, Seeger H, Lippert TH. Estradiol metabolism and
malignant disease. Maturitas. 2002 Sep;43(1):1–10.
64. Spyridopoulos I, Sullivan AB, Kearney M, Isner JM, Losordo
DW. Estrogen-Receptor–Mediated Inhibition of Human
Endothelial Cell Apoptosis. Circulation. 1997 Mar 18;95(6):1505
LP – 1514.
65. Sanz-Gonzalez SM, Cano A, Valverde MA, Hermenegildo C,
Andres V. Drug targeting of estrogen receptor signaling in the
cardiovascular system: preclinical and clinical studies. Curr Med
Chem Cardiovasc Hematol Agents. 2004;2(2):107–22.
66. Guo Y-L, Wang S, Colman RW. Kininostatin, an Angiogenic
Inhibitor, Inhibits Proliferation and Induces Apoptosis of Human
Endothelial Cells. Arterioscler Thromb Vasc Biol.
2001;21(9):1427–33.
Impact of bazedoxifene on endothelial health markers 
179
67. Simoncini T, Genazzani AR, Liao JK. Nongenomic mechanisms
of endothelial nitric oxide synthase activation by the selective
estrogen receptor modulator raloxifene. Circulation.
2002;105(11):1368–73.
68. Oviedo PJ, Hermenegildo C, Tarín JJ, Cano A. Raloxifene
promotes prostacyclin release in human endothelial cells through a
mechanism that involves cyclooxygenase-1 and -2. Fertil Steril.
2005;83(6):1822–9.
69. Mori-Abe  a, Tsutsumi S, Takahashi K, Toya M, Yoshida M, Du
B, et al. Estrogen and raloxifene induce apoptosis by activating
p38 mitogen-activated protein kinase cascade in synthetic vascular
smooth muscle cells. J Endocrinol. 2003;178(3):417–26.
70. Oviedo PJ, Hermenegildo C, Tarín JJ, Cano A. Raloxifene
increases proliferation of human endothelial cells in association
with increased gene expression of cyclins A and B1. Fertil Steril.
2007;88(2):326–32.
71. Marín F, Barbancho MC. Clinical pharmacology of selective
estrogen receptor modulators (SERMs). Sel Estrogen Recept
Modul A New Brand Multitarg Drugs. 2006;49–69.
72. Mirkin S, Pickar JH. Selective estrogen receptor modulators
(SERMs): A review of clinical data. Vol. 80, Maturitas. 2015. p.
52–7.
73. Wickerham L. Tamoxifen--an update on current data and where it
can now be used. Breast Cancer Res Treat. 2002;75 Suppl 1:S7-
12; discussion S33-5.
74. Gradishar WJ, Jordan VC. Clinical potential of new antiestrogens.





75. Jordan VC. Antiestrogens and selective estrogen receptor
modulators as multifunctional medicines. 2. Clinical
considerations and new agents. Vol. 46, Journal of Medicinal
Chemistry. 2003. p. 1081–111.
76. Top S, Vessières A, Pigeon P, Rager MN, Huché M, Salomon E,
et al. Selective estrogen-receptor modulators (SERMs) in the
cyclopentadienylrhenium tricarbonyl series: Synthesis and
biological behaviour. ChemBioChem. 2004;5(8):1104–13.
77. Vogel CL, Johnston MA, Capers C, Braccia D. Toremifene for
breast cancer: A review of 20 years of data. Vol. 14, Clinical
Breast Cancer. 2014. p. 1–9.
78. Gizzo S, Saccardi C, Patrelli TS, Berretta R, Capobianco G, Gangi
S Di, et al. Update on raloxifene: Mechanism of action, clinical
efficacy, adverse effects, and contraindications. Obstet Gynecol
Surv. 2013 Jun;68(6):467-81.
79. Blumenthal RS, Baranowski B, Dowsett SA. Cardiovascular
effects of raloxifene: The arterial and venous systems. Vol. 147,
American Heart Journal. 2004. p. 783–9.
80. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D,
Kornitzer M, et al. Effects of raloxifene on cardiovascular events
and breast cancer in postmenopausal women. N Engl J Med.
2006;355(2):125–37.
81. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini
RS, Atkins JN, et al. Update of the national surgical adjuvant
breast and bowel project Study of Tamoxifen and Raloxifene
(STAR) P-2 trial: Preventing breast cancer. Cancer Prev Res.
2010;3(6):696–706.
82. Dhingra K. Antiestrogens--tamoxifen, SERMs and beyond. Invest
New Drugs. 1999;17(3):285–311.
Impact of bazedoxifene on endothelial health markers 
181
83. Downs RW, Moffett AM, Ghosh A, Cox DA, Dowsett SA, Harper
K. Effects of arzoxifene on bone, lipid markers, and safety
parameters in postmenopausal women with low bone mass.
Osteoporos Int. 2010;21(7):1215–26.
84. Ke HZ, Brown TA, Thompson DD. Lasofoxifene (CP-336,156), a
novel selective estrogen receptor modulator, in preclinical studies.
J Am AGING Assoc. 2002;25(2):87–99.
85. Cummings SR, Ensrud K, Delmas PD, Lacroix AZ, Vukicevic S,
Reid DM, et al. Lasofoxifene in postmenopausal women with
osteoporosis. Obstetrical and Gynecological Survey. 2010 Feb
25;362(8):686-96.
86. Blizzard TA, Morgan, II JD, Mosley RT, Birzin ET, Frisch K,
Rohrer SP, et al. 2-Phenylspiroindenes: a novel class of selective
estrogen receptor modulators (SERMs). Bioorg Med Chem Lett.
2003 Feb;13(3):479–83.
87. Greenberger LM, Annable T, Collins KI, Komm BS, Lyttle CR,
Miller CP, et al. A New Antiestrogen, 2-(4-Hydroxy-phenyl)-3-
methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol
hydrochloride (ERA-923), Inhibits the Growth of Tamoxifen-
sensitive and -resistant Tumors and Is Devoi. Clin Cancer Res.
2001 Oct 1;7(10):3166 LP – 3177.
88. Kawate H, Takayanagi R. Efficacy and safety of bazedoxifene for
postmenopausal osteoporosis. Vol. 6, Clinical Interventions in
Aging. 2011. p. 151–60.
89. McDonnell DP. The molecular pharmacology of estrogen receptor






90. Simoncini T, Genazzani AR. Raloxifene Acutely Stimulates Nitric
Oxide Release from Human Endothelial Cells Via an Activation
of Endothelial Nitric Oxide Synthase. J Clin Endocrinol Metab.
2000;85(8):2966–9.
91. Oviedo PJ, Hermenegildo C, Cano A. Raloxifene increases the
capacity of serum to promote prostacyclin release in human
endothelial cells: Implication of COX-1 and COX-2. Menopause.
2004;11(4):430–7.
92. Cano  a, Hermenegildo C, Oviedo P, Tarín JJ. Selective estrogen
receptor modulators and risk for coronary heart disease.
Climacteric. 2007;10(2):97–111.
93. Carneiro ALB, De Cassia De Maio Dardes R, Haidar MA.
Estrogens plus raloxifene on endometrial safety and menopausal
symptoms-semisystematic review. Vol. 19, Menopause. 2012. p.
830–4.
94. Ronkin S, Northington R, Baracat E, Nunes MG, Archer DF,
Constantine G, et al. Endometrial effects of bazedoxifene acetate,
a novel selective estrogen receptor modulator, in postmenopausal
women. Obstet Gynecol. 2005;105(6):1397–404.
95. Ethun KF, Wood CE, Register TC, Cline JM, Appt SE, Clarkson
TB. Effects of bazedoxifene acetate with and without conjugated
equine estrogens on the breast of postmenopausal monkeys.
Menopause. 2012;19(11):1242–52.
96. Palacios S. Efficacy and safety of bazedoxifene, a novel selective
estrogen receptor modulator for the prevention and treatment of
postmenopausal osteoporosis. Curr Med Res Opin.
2010;26(7):1553–63.
97. Gruber C, Gruber D. Bazedoxifene (Wyeth). Curr Opin Investig
Drugs. 2004;5(10):1086–93.
Impact of bazedoxifene on endothelial health markers 
183
98. Komm BS, Kharode YP, Bodine PVN, Harris HA, Miller CP,
Lyttle CR. Bazedoxifene acetate: A selective estrogen receptor
modulator with improved selectivity. Endocrinology.
2005;146(9):3999–4008.
99. Palacios S, Silverman SL, de Villiers TJ, Levine AB, Goemaere S,
Brown JP, et al. A 7-year randomized, placebo-controlled trial
assessing the long-term efficacy and safety of bazedoxifene in
postmenopausal women with osteoporosis. Menopause.
2015;22(8):806–13.
100.  de Villiers TJ, Chines AA, Palacios S, Lips P, Sawicki AZ, Levine 
AB, et al. Safety and tolerability of bazedoxifene in 
postmenopausal women with osteoporosis: results of a 5-year, 
randomized, placebo-controlled phase 3 trial. Osteoporos Int. 
2011;22(2):567–76. 
101.  Komm BS, Chines AA. Bazedoxifene : the evolving role of third-
generation selective estrogen- receptor modulators in the 
management of postmenopausal osteoporosis. Ther Adv 
Musculoskelet Dis. 2012 Feb;4(1):21-34. 
102.  Miller PD, Chines AA, Christiansen C, Hoeck HC, Kendler DL, 
Lewiecki EM, et al. Effects of Bazedoxifene on BMD and Bone 
Turnover in Postmenopausal Women: 2-Yr Results of a 
Randomized, Double-Blind, Placebo-, and Active-Controlled 
Study. J Bone Miner Res. 2007;23(4):525–35.  
103.  Xu L, Tsai KS, Kim GS, Wu Y, Vincendon P, Chines AA, et al. 
Efficacy and safety of bazedoxifene in postmenopausal Asian 
women. Osteoporos Int. 2011;22(2):559–65.  
104.  Chaplin S. Duavive HRT: conjugated oestrogens with 





105.  Crabtree JS, Peano BJ, Zhang X, Komm BS, Winneker RC, Harris 
HA. Activity of three selective estrogen receptor modulators on 
hormone-dependent responses in the mouse uterus and mammary 
gland. Mol Cell Endocrinol. 2008;287(1–2):40–6.  
106.  Komm BS, Mirkin S. An overview of current and emerging 
SERMs. J Steroid Biochem Mol Biol. 2014 Sep;143:207-22. 
107.  Berrodin TJ, Chang KCN, Komm BS, Freedman LP, Nagpal S. 
Differential biochemical and cellular actions of Premarin 
estrogens: Distinct pharmacology of bazedoxifene-conjugated 
estrogens combination. Mol Endocrinol. 2009;23(1):74–85.  
108.  Kharode Y, Bodine PVN, Miller CP, Lyttle CR, Komm BS. The 
pairing of a selective estrogen receptor modulator, bazedoxifene, 
with conjugated estrogens as a new paradigm for the treatment of 
menopausal symptoms and osteoporosis prevention. 
Endocrinology. 2008;149(12):6084–91.  
109.  Stovall DW, Utian WH, Gass MLS, Qu Y, Muram D, Wong M, et 
al. The effects of combined raloxifene and oral estrogen on 
vasomotor symptoms and endometrial safety. Menopause. 
2007;14(3):510–7. 
110.  Lobo RA, Pinkerton JA V., Gass MLS, Dorin MH, Ronkin S, 
Pickar JH, et al. Evaluation of bazedoxifene/conjugated estrogens 
for the treatment of menopausal symptoms and effects on 
metabolic parameters and overall safety profile. Fertil Steril. 
2009;92(3):1025–38. 
111.  Pinkerton J V, Komm BS, Mirkin S. Tissue selective estrogen 
complex combinations with bazedoxifene/conjugated estrogens as 
a model. 2013;618–28.  
 
Impact of bazedoxifene on endothelial health markers 
185
112.  Clarkson TB, Ethun KF, Chen H, Golden D, Floyd E, Appt SE. 
Effects of bazedoxifene alone and with conjugated equine 
estrogens on coronary and peripheral artery atherosclerosis in 
postmenopausal monkeys. Menopause. 2013; 20(3) 274-281. 
113.  Pfaffl MW. A new mathematical model for relative quantification 
in RT-PCR. Nucleic Acids Res. 2001;29(9):16–21.  
114.  Iwata BA, Hanley GP, McCord BE. Functional analysis of 
problem behavior: a review. J Appl Behav Anal. 2003;2(2):147–
85.  
115.  Valveny N, Gilliver S. How to interpret and report the results from 
multivariable analyses Correspondence to : Variables : Med Writ. 
2016; 25(3) 37-42. 
116.  Sacks T, Moldow CF, Craddock PR, Bowers TK. Oxygen 
Radicals Mediate Endothelial Cell Damage by Complement-
Stimulated Granulocytes AN IN VITRO MODEL OF IMMUNE 
VASCULAR DAMAGE. :1161–7.  
117.  Aranguren XL, Agirre X, Beerens M, Coppiello G, Uriz M, 
Vandersmissen I, et al. Unraveling a novel transcription factor 
code determining the human arterial-specific endothelial cell 
signature. Blood. 2013;122(24):3982–92.  
118.  Onat D, Brillon D, Colombo PC, Schmidt AM. Human vascular 
endothelial cells: A model system for studying vascular 
inflammation in diabetes and atherosclerosis. Curr Diab Rep. 
2011;11(3):193–202.  
119.  Soernes T, Bakke T. The length of the human umbilical cord in 





120.  Polchow B, Kebbel K, Schmiedeknecht G, Reichardt A, Henrich 
W, Hetzer R, et al. Cryopreservation of human vascular umbilical 
cord cells under good manufacturing practice conditions for future 
cell banks. J Transl Med. 2012;10(1):1–17.  
121.  Krasinski K, Spyridopoulos I, Asahara T, van der Zee R, Isner JM, 
Losordo DW. Estradiol accelerates functional endothelial recovery 
after arterial injury. Circulation. 1997;95(7):1768–72.  
122.  Mendelsohn ME, Karas RH. The Protective Effects of Estrogen on 
the Cardiovascular System. N Engl J Med. 1999 Jun 
10;340(23):1801-11. 
123.  Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence 
JB, et al. Effects of raloxifene on serum lipids and coagulation 
factors in healthy postmenopausal women. J Am Med Assoc. 1998 
May 13;279(18):1445-51. 
124.  Sack MN, Rader D, Cannon RO. Oestrogen and inhibition of 
oxidation of low-density lipoproteins in postmenopausal women. 
Lancet. 1994; Jan 29;343(8892):269-70. 
125.  Colacurci N, Manzella D, Fornaro F, Carbonella M, Paolisso G. 
Endothelial function and menopause: Effects of raloxifene 
administration. J Clin Endocrinol Metab. 2003 May;88(5):2135-
40. 
126.  Myers SI. COX-2-Derived Prostacyclin Confers Atheroprotection 
on Female Mice. Perspect Vasc Surg Endovasc Ther. 2005  
Sep;17(3):270-1. 
127.  Takahashi K, Ohmichi M, Yoshida M, Hisamoto K, Mabuchi S, 
Arimoto-Ishida E, et al. Both estrogen and raloxifene cause G1 
arrest of vascular smooth muscle cells. J Endocrinol. 2003 
Aug;178(2):319-29. 
Impact of bazedoxifene on endothelial health markers 
187
128.  Christiansen C, Chesnut CH, Adachi JD, Brown JP, Fernandes 
CE, Kung AWC, et al. Safety of bazedoxifene in a randomized, 
double-blind, placebo- and active-controlled phase 3 study of 
postmenopausal women with osteoporosis. BMC Musculoskelet 
Disord. 2010 Jun 22;11:130. 
129.  Clarkson TB, Ethun KF, Pajewski NM, Golden D, Floyd E, Appt 
SE. Effects of bazedoxifene, conjugated equine estrogens, and a 
tissue-selective estrogen complex containing both bazedoxifene 
and conjugated equine estrogens on cerebral artery atherosclerosis 
in postmenopausal monkeys. Menopause. 2014;21(1):8–14.  
130.  Ishibashi Y, Matsui T, Ueda S, Fukami K, Okuda S, Ohta H, et al. 
Bazedoxifene blocks ages-rage-induced superoxide generation and 
MCP-1 level in endothelial cells. Climacteric. 2015;18(3):426–30.  
131.  Spyridopoulos I, Andrés V. Control of vascular smooth muscle 
and endothelial cell proliferation and its implication in 
cardiovascular disease. 1998; 2:81-89. 
132.  Frasor J, Danes JM, Komm B, Chang KENCN, Lyttle CR, 
Katzenellenbogen BS, et al. Profiling of Estrogen Up- and Down-
Regulated Gene Expression in Human Breast Cancer Cells : 
Insights into Gene Networks and Pathways Underlying Estrogenic 
Control of Proliferation and Cell Phenotype. 2003;144(10):4562–
74.  
133.  Yu X, Zhang X, Dhakal IB, Beggs M, Kadlubar S, Luo D. 
Induction of cell proliferation and survival genes by estradiol-
repressed microRNAs in breast cancer cells. BMC Cancer. 2012 
Jan 20;12:29. 
134.  Edeuilh GER. Estrogen induction of the cyclin D1 promoter : 






135.  Koroxenidou L, Ohlson LCE, Ha IP. Long-term 17 a -ethinyl 
estradiol treatment decreases cyclin E and cdk2 expression, 
reduces cdk2 kinase activity and inhibits S phase entry in 
regenerating rat liver. 2005;43:478–84.  
136.  Liang W, Zhou X, Yao L, Liu B. Cryopreservation-Altered 
Expression. 2017;15(3):176–81.  
137.  Mutter GL, Zahrieh D, Liu C, Neuberg D, Finkelstein D, Baker 
HE, et al. Comparison of frozen and RNALater solid tissue 
storage methods for use in RNA expression microarrays. 
2004;7:1–7.  
138.  Marienfeld. Rejillas de recuento. 2013;2015(23 Marzo):58–62.  
9. APPENDIX
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9.1 Cell count 
Quantification of endothelial cells was performed using an optical 
inverted microscope, in which the original substrate was analyzed 
directly by phase contrast. Cell count was carried out by dilution method 
over a Neubauer chamber using trypan blue, a dye which contains amino 
and sulfate groups, allowing us to distinguish between viable and 
nonviable cells. Notable among its properties are high toxicity and 
solubility in water. This preparation proved to be of great help in 
calculating the cells and their viability, as the ions prevent them from 
passing through the membranes of the intact cells, so they stain only 
damaged or dead cells. 
The Neubauer chamber grid has a depth of 0.1 mm, optimal to 
adapt to the optical microscope. The grid contains nine large squares, 
each with a 1mm2 area. The large squares are separated by triple lines 
with a 0.025 mm space between them, and are subdivided into 4x4 
groups of  0.2 x 0.2 mm2 squares (Figure 25A).  
We took 15 μl of medium with cell suspension and diluted it with 
15 μl of 0.4% trypan blue solution, prepared in 0.8% sodium chloride 
and 0.06% potassium phosphate dibasic (Trypan Blue Solution 0,4%, 
SIGMA). The mixture was placed in Eppendorf-type bottles and 
incubated for 5 min at room temperature. With the help of a pipette, 10 
μl was injected from one side into the Neubauer chamber. We proceeded 

Impact of bazedoxifene on endothelial health markers 
193
9.2 Cryopreservation of human endothelial cells 
A proportion of the endothelial cells obtained from the first three 
cords were treated with Dimethyl Sulfoxide-based (DMSO) 
cryoprotective agent solutions, then resuspended in freezing medium and 
were slowly frozen overnight in an isopropanol bath freezing container at 
-80ºC, then transferred to liquid nitrogen to be stored at 195.8ºC. For 
recovery from cryopreservation, all cells were thawed at room 
temperature after a slightly variable period of time of cryopreservation 
(3-3.5 months) and promptly were resuspended drop by drop with 
prewarmed culture medium. The cells were then centrifuged, washed, 
and resuspended in culture medium to remove residual dimethyl 
sulfoxide and plated on pre-coated standard tissue culture plates. The 
medium was changed the next day, and the cells were passaged when 
confluence was reached. 


